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RESUMO  
 
Desde 1959, o papel da Farmacogenómica na sociedade tem-se revelado cada 
vez mais importante. Nesta área, têm particular interesse as variações genéticas 
localizadas em genes envolvidos na resposta a fármacos, de modo a inferir a dose certa 
a administrar. Deste modo a definição “medicina personalizada” tem sido um dos 
objetivos da farmacogenómica, sobrevalorizando cada vez mais a máxima, “the right 
dose of the right drug to the right person”. No entanto, os efeitos adversos a fármacos 
são a causa de uma percentagem elevada dos internamentos a nível mundial e 
poderiam ser facilmente reduzidos recorrendo a testes de farmacogenómica. 
O corpo humano está exposto a um elevado número de xenobióticos, incluindo 
uma enorme variedade de componentes farmacêuticos. Deste modo, de forma a 
reduzir os efeitos adversos que poderiam advir desta exposição, o organismo humano 
desenvolveu mecanismos enzimáticos de destoxificação, sendo as enzimas da família 
citocromo P450 um exemplo disso, em particular a CYP2D6. 
A CYP2D6 é uma das enzimas mais amplamente estudadas e intervém na 
destoxificação de xenobióticos. Para além disso, tem uma elevada relevância no 
metabolismo hepático de agentes terapêuticos como é o caso de antidepressores, 
neuroléticos, antiarrítmicos, analgésicos, entre outros, também tem um papel relevante 
no metabolismo de substâncias endógenas, tais como percursor da dopamina. 
Relativamente aos analgésicos, destaca-se o exemplo da morfina, utilizada no presente 
estudo.  
A morfina é o opióide mais usado para o tratamento da dor e o seu efeito 
analgésico está associado a alguns efeitos secundários associados, como é o caso de 
náuseas, vómitos e prurido. A morfina atua pela ativação do recetor miu opióide e a 
dopamina é libertada no núcleo accumbens em consequência desta ação. Para além 
disso, salientam-se algumas diferenças no grau de diminuição de dor após a sua 
administração e foi descrito que 10-15% das mulheres sofrem de dor crónica 
persistente após cesariana. 
Deste modo, foi realizado este estudo numa população de puérperas caucasianas 
submetidas a cesariana e às quais foram administradas 2,5mg de morfina. Assim, foi 
efetuada uma interpretação farmacogenética para avaliar a previsão do perfil 
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metabólico com base nas variantes genéticas do CYP2D6 e a sua relação com os scores 
clínicos de dor e efeitos secundários associados à morfina, anteriormente 
mencionados. Para isso, foi realizada a determinação do número de cópias do gene 
CYP2D6 e efetuada a genotipagem para as variantes alélicas CYP2D6*1, *2, *3, *4, *5, 
*6, *10, *17 e *41, através de Real-Time PCR. Os parâmetros avaliados foram a dor 
(medida após, 4, 8 e 12 horas e quantificada numa escala de 0 a 10) e o aparecimento 
de prurido. 
Após a análise estatística dos resultados, concluiu-se que os haplótipos que 
resultam na ausência e redução da função da enzima estão positivamente 
correlacionados com elevados scores de dor. Este facto está positivamente associado à 
diminuição da síntese de dopamina pela via da tiramina. Consequentemente, a ativação 
da via de transdução do sinal que controla a dor e o efeito analgésico poderá estar 
reduzida, levando ao aumento da dor após cesariana. 
Este trabalho contribui para um melhor entendimento de como as variantes 
alélicas do CYP2D6 podem afetar a dor, aumentando o conhecimento acerca do 
tratamento associado à analgesia pós-parto (cesariana). 
   
Palavras-chave: CYP2D6; Farmacogenómica; Cesariana; Dor; Analgesia  
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SUMMARY 
 
Since 1959, the role of the Pharmacogenomics in society has become increasingly 
important. In this area, genetic variations located in genes involved in drug response 
have particular interest, in order to infer the right dose levels. Thus a "personalized 
medicine" definition has been an objective of pharmacogenomics, overvaluing the 
paradigm, "the right dose of the right drug to the right person." However, adverse 
drug effects are the cause of a high percentage of admissions worldwide and it could 
be easily reduced using pharmacogenomics testing.  
The human body is exposed to a large number of xenobiotics, including a huge 
variety of pharmaceutical compounds. Thus, in order to reduce the adverse effects 
that could arise from this exposure, the human body has developed a detoxification 
enzyme mechanisms, and the cytochrome enzymes P450 family are an example, in 
particular CYP2D6.  
The CYP2D6 is one of the most widely studied enzymes and it is involved in the 
detoxification of xenobiotics. In addition, it has a high relevance in hepatic metabolism 
of therapeutic agents such as antidepressants, neuroleptics, antiarrhythmics, analgesics, 
among others, also playings an important role in the metabolism of endogenous 
substances such as dopamine precursor. Regarding analgesics, it stands out the 
example of morphine used in the present study.  
Morphine is the most commonly used opioid for the treatment of pain and its 
analgesic effect is associated with some side effects such as nausea, vomiting, and 
pruritus. Morphine acts by activation of miu opioid receptor and dopamine is released 
in the nucleus accumbens as a result of this action. In addition, we highlight a few 
differences in the degree of reduction of pain after administration and it was described 
that 10-15% of women suffer from chronic persistent pain after cesarean section.  
This study was conducted in a population of Caucasian parturient undergoing 
cesarean section and who were administered with 2.5mg of morphine. Therefore, a 
pharmacogenetics interpretation was conducted to evaluate the prediction of 
metabolic profile based on genetic variants of CYP2D6 and its relationship with clinical 
scores for pain and side effects associated with morphine, previously mentioned. The 
determination of the CYP2D6 gene copy number and the genotyping for allelic variants 
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CYP2D6*1, *2, *3, *4, *5, *6, *10, *17 and *41 by Real-Time PCR. The evaluated 
parameters were pain (measured after 4, 8 and 12 hours and quantified in a 0-10 scale) 
and the appearance of pruritus.  
After statistical analysis of the results, it was found that haplotypes that result in 
the absence or reduced function of the enzyme are positively correlated with high 
scores for pain. This fact is positively associated with dopamine synthesis decreased by 
tyramine’s pathway. Consequently, the activation of the signal transduction pathway 
that controls pain and analgesic effect may be reduced, leading to increased pain after 
cesarean section.  
This work contributes to a better understanding of how the allelic variants of 
CYP2D6 may affect pain, increasing knowledge about treatment associated with 
postpartum analgesia (cesarean). 
 
Key-words: CYP2D6; Pharmacogenetics; Cesarean; Pain; Analgesia  
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1. History 
 
Physicians have long been aware of the subtle differences in the responses of 
patients to medication. 
In the last century, the physiologist Archibald Garrod develops the concept of 
“chemical individuality” (1902-1909). It was the first time that the concept of genetic 
variations might modulate variability in drug effects was proposed1. Then, in the 1950s 
others developments took place. In 1956, the association of primaquine-induced 
hemolysis with glucose-6-phosphate-dehydrogenase deficiency in erythrocytes was 
discovered. In 1957 twin studies indicated polygenic influences on the 
pharmacokinetics of numerous drugs2. 
The term pharmacogenetics was coined in 1959, and the first textbook was 
published in 1962, before methods for studying DNA sequence variation were 
available3. Then, the first time that the “pharmacogenetics” term appears in the 
literature was in 1959 by Friedrich Vogel4. 
The field of pharmacogenetics had new developments in the 1970s, when Vesell 
and colleagues demonstrated that plasma half-lives of many drugs were less divergent 
among monozygotic twin pairs than dizygotic twin pairs2. Over 50 years, examples of 
novel drug effects exaggerated responses or lack of effectiveness of drugs, as a 
manifestation of inherited individual traits have been observed. More recently, 
developments have broadened pharmacogenetic approaches to include novel genomic 
techniques with introduction of the term pharmacogenomics in the 1990's with 
emergence of the Human Genome Project5.  
In 2005, the first case of fatal respiratory depression in a breastfed 13-day-old 
neonate whose codeine-prescribed mother was a Cytochrome 2D6 (CYP2D6) 
ultrarapid metabolizer (UM) was described6. Neonatal post-mortem blood contained a 
high concentration of morphine, and breast milk morphine concentration was four fold 
higher than any previous literature report. The death was attributed to opioid 
intoxication as a result of almost two week exposure to higher than expected 
morphine dose excreted into breast milk of an ultrarapid metabolizing mother. The 
breastfeeding mother herself also experienced sedation and constipation and needed 
to halve her codeine (3-methilmorphine) dose accordingly. As a result of this case, the 
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United States Food and Drug Administration (FDA) and Health Canada have issued 
public health advisories and a proposed labelling update with the caution that codeine 
may not be safe during breastfeeding for infants whose mothers are CYP2D6 UMs6. 
There are many examples in literature stressing out the importance of genetics 
influence in drug response. Scientists are increasingly learning more about the 
interaction between drugs and human genetics and the paradigm “the right dose of the 
right drug to the right person” is even more overvalued.  This is one of the goals of 
pharmacogenomics and personalized medicine7. 
 
 
 
2. Pharmacogenetics and pharmacogenomics 
 
Findings from the Human Genome Project results made it clear that 99.9% of the 
information in the genomes containing the estimated 20,000 human genes, is identical 
from one person to the other 20,000. The differences in the remaining 0.1% of genes 
present in the human cells are keys to individuality, including the influence in an 
individual’s susceptibility to certain health problems or determine how one reacts to 
different treatments8,9. 
In a large patient population, a medication that is proven efficacious in many 
patients often fails to work in some other subjects. Furthermore, when it does work, it 
may cause serious side effects, even death, in some patients. Factors that cause 
variations in drug response are multifold and complex, some of which involve 
fundamental aspects of human biology, because a drug response directly affects well 
being and survival10. 
Pharmacogenomics, takes use of a genome wide approach to study the entire 
spectrum of genes involved in drug response, for providing the base for a more 
rational approach for prescription drugs11,12.  
This concept refers to the complex interactions of genes across the genome and 
includes identifying candidate genes and polymorphisms, correlating these 
polymorphisms with possible therapies, predicting drug response and clinical 
outcomes, reducing adverse events and dosing of therapeutic drugs on the basis of 
genotype13.  
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In summary, pharmacogenetics focuses on a single gene while pharmacogenomics 
studies multiple genes14.  
One goal of pharmacogenomics is to customize drugs for defined sub-
populations of patients, and eventually, perhaps tailor therapies for specific individuals 
(Figure 1)13 with specific genetic characteristics.  
 
 
 
 
Figure 1 – An ultimate clinical goal of pharmacogenomics. 1. At present, only a limited number of 
patients are treated with a specific drug for any given disease due to adverse events and not all respond. 
2. Pharmacogenomics allows ‘tailor’ therapies, so that, all patients who have a given disease will receive 
different drugs on adjusted doses, responding to therapy with less risk of adverse events13 (Adapted 
from Issa, 2002). 
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So that, pharmacogenetics and pharmacogenomics (PGx) have a potential role in 
reducing Adverse Drug Reactions (ADRs) that have been reported to be the cause for 
drug withdrawal after marketing, hospital admissions, death in hospitalized patients and 
to be the fourth leading cause of death in developed countries ahead of pulmonary 
disease, diabetes, AIDS, pneumonia, accidents, and automobile deaths. The costs 
associated with ADRs may radically escalate the cost for healthcare14,15. 
Pharmacogenomics is a highly attractive field of research, which has been 
recently stimulated by multi-omics technologies16. In fact, Genome-Wide Association 
Studies (GWAS) may help to identify multiple variants that might incrementally affect 
response to a particular drug at the same time17. 
A substantial improvement may be expected over the next few decades through 
development of procedures, their medical availability, and through reduction of the 
methods costs, which will allow effective screening of a patient for genes that control 
his or her response to a given drug (Figure 2), influencing ADRs.  
Presently a document is on public discussion about incorporation of 
Pharmacogenetics in clinical trials18. 
 
 
Figure 2 – Contrasting approaches to incorporating genomic information into prescribing. Current 
practice vs future approach3 (Adapted from Roden et al, 2011). 
 Rosa Quinta, 2014  Page 5 
3. Adverse Drug Reactions (ADRs) 
 
Pharmacogenetics is the science that understanding of the role that an 
individual’s genetic variations play in xenobiotics aims the response, including drugs, as 
well as what side effects are likely to occur. It is important to regulate this subject in 
order to minimize the ADRs, make decisions based on risk/benefit criteria, and allow 
the rational use of drugs based on other criteria8. So, this science starts with the 
observation of an unexpected drug response and continues for finding a genetic cause 
for that effect. 
The ADRs are unpredictable, even among individuals who are receiving the same 
therapeutic regimen19. When chosing a drug, physicians need to consider the risk of 
adverse events, or any detrimental, unintended consequence of administering a drug at 
indicated clinical doses9. ADRs caused more 
than 2 million hospitalizations including 100,000 
deaths per year in the United States, according 
to data from 2006. The ADRs could be due to 
multiple factors such as disease determinants, 
environmental and genetic factors12. 
Many drug responses appear to be 
genetically determined and the relationship 
between genotype and drug response may have 
a very relevant diagnostic value. Moreover, the 
genetics of the drug metabolizing enzymes 
plays a critical role for understanding 
interindividual differences in drug response and 
ADRs20. 
Interindividual variability in drug 
response, including ADRs, is a consequence of 
multiple factors, including genomics, 
epigenomics, environment and a patient’s 
characteristics, such as gender, age and/or 
concomitant medication16 (Figure 3). 
Figure 3 – Interindividual variation in drug 
response is the consequence of a combination 
of genetic and environmental factors as well as 
patient’s individual characteristics17 (Adapted 
from Schwab, 2012). 
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Although individualized medications remain as a challenge for the future, the 
pharmacogenetic approach in drug development should be still continued. If it becomes 
a reality, it delivers benefits to improve public health and allow genetically subgroup 
diseases thereby avoiding adverse drug reactions12. 
In figure 4, the progression of ADRs’ notification in Portugal is represented, 
showing the increase in past years. 
 
 
Figure 4 – Evolution of the annual number of ADRs reports (1992-2011). Pharmacovigilance started in 
2000. This contribute to the increase of notification’s number per year. The number of notifications in 
2011 is 4 times greater than in 200021 (Adapted from INFARMED, 2011). 
 
 
4. Opioids and pain treatment 
 
Clinicians are well aware of the large and unpredictable interindividual variability 
in pain perception and sensitivity to analgesia.  
Pain is a major public health issue, and it is the most common reason for 
physician consultation in the United States. However, despite a wide variety of 
pharmacological agents available on the market, many people cannot achieve optimal 
analgesia, and inadequate treatment remains a major cause of suffering and disapproval 
in pain therapy22. 
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4.1. Mechanisms mediating pain 
 
In order to understand nociception, it is essential to understand the mechanism 
behind it and only then is it possible to specifically target the source of the pain 
stimulus23.  
Pain and inflammatory stimuli result in a series of diverse effects, including pain 
transduction, sensitization of central nervous system and peripheral nerve endings23. 
Nociceptors, or receptors of pain, do not have a continuous function under 
normal activity, but, when stimulated upon pain stimuli or when tissue irritation or 
injury occurs, they respond with a magnitude relevant to the degree of the stimulus23. 
Epidural analgesia with a combination of local anesthetics and opioids is an 
excellent multimodal method for better analgesia and enhanced recovery. Epidural 
analgesia should not be considered as a single generic entity because many factors like 
the congruency of catheter insertion location to site of surgical incision, type of 
analgesic regimen whether local anesthetic or opioids, and also the type of pain 
assessments which can be either at rest or dynamical. Epidural analgesia, regardless of 
analgesic agent, location of catheter placement, and type and time of pain assessment, 
provided better postoperative analgesia compared with parenteral opioids23.  
However, there is a central role for dopamine (DA) neurotransmission in 
modulation of pain perception and analgesia. Opioid system activity is related to pain 
processing and has also been linked with DA neurotransmission. The DA and opioid 
systems may work together in the context of pain processing, with the opioid system 
responding rapidly to noxious stimuli, which in turn promotes DA release.  
In addition to the anatomical overlap between brain regions associated with pain 
processing and those that comprise the DA system, there is also a substantial overlap 
between the cognitive and emotion-associated factors that influenced by DA 
neurotransmission and the cognitive and affective factors that influence the experience 
of pain. Dopaminergic neurotransmission has an important influence on outcome 
prediction, attention, response inhibition, and motivation, as well as affective symptoms 
associated with anxiety and depression24.  
The epidural administration of morphine in obstetrics aims to promote analgesia 
in women undergoing cesarean section. The figure 5 is a general representation of 
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nociception postpartum pain, and it is possible verify that, opiate drugs (morphine), 
which act primarily in the central nervous system, block the transfer of pain signals 
from the brain to the spinal cord. Thus, morphine exerts its analgesic effect by binding 
to presynaptic miu-opioid receptor in sensory neurons, mimetizing the action of 
endorphins. Consequently, there is hyperpolarization of the neuron and reducing the 
release of neurotransmitters, particularly dopamine and serotonin by blocking the 
perception of pain signals25.  
 
 
Figure 5 – Representation of a pain nociception mechanism15  
(Adapted from Gasche et al, 2004). 
 
 
Pain relief can be attained by the conventional pharmacological option of 
administering opioids, such as morphine.  
Morphine has been the analgesic drug of choice for anesthesia for decades. The 
adverse effects of such opioids are quite common and patients frequently have nausea, 
vomiting, pyrexia, pruritus and hypotension23. 
Pain relief by epidural and spinal anesthesia or combined spinal-epidural 
anesthesia have found major success in obstetric procedures because of the major 
advantage over general anesthesia and thus the parturient can stay awake during a 
cesarean section23. 
 Rosa Quinta, 2014  Page 9 
In the presently accepted definition, ‘Pain’ is described as an unpleasant sensory 
and emotional experience associated with real or potential tissue damage, or described 
in terms of such damage – IASP, International Association Study of Pain23,26,27.  
Pain is also considered (EFIC) as a private perception that arises to the conscious 
brain, typically in response to noxic stimuli, but sometimes also in its absence.28 
Pain perception is a diverse set of complex perceptual events (including 
neurotransmitters and hormones) that are characterized by their unpleasant or 
distressing nature29,30. 
In the clinical setting, subjective patient self-reported pain severity ratings that 
encompass both nociceptive (pain) stimulus intensity and the patient’s response to the 
stimulus are used to guide analgesic drug treatment, as there are no objective “pain 
tests” that can be readily applied at the bedside or in the primary care physician’s 
office31. 
Nociception is the physiologic component of pain and includes transduction, 
transmission and modulation of nociceptive stimuli. If nociceptive stimuli be 
determined, several neuroendocrine responses occur, and a hiperexcitability state of 
the periferic and central nervous system is already installed26. 
The sensation of pain produced by an acute insult such as trauma or surgery is an 
adaptive response characterized by guarding behavior to facilitate healing and is an 
important survival mechanism. Globally, the prevalence of pain is about 15–20%, in 
adults, and not only adversely affects patient quality of life but it also imposes a high 
socioeconomic cost encompassing work days lost, reduced productivity and increased 
healthcare costs. So, the use of opioids in pain management requires careful dose 
escalation and empirical adjustments based on clinical response and the presence of 
side effects or ADRs31,32.  
Pain severity ratings and the analgesic dosing requirements of patients with 
apparently similar pain conditions may differ considerably between individuals. 
Contributing factors include those of genetic and environmental origin with epigenetic 
mechanisms that enable dynamic gene-environment interaction, more recently 
implicated in pain modulation31. 
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Indeed, more than 350 candidate pain genes have been identified as potentially 
contributing to heritable differences in pain sensitivity. A large number of genetic 
association studies conducted in patients with a variety of clinical pain types or in 
humans exposed to experimentally induced pain stimuli in the laboratory setting, have 
examined the impact of single-nucleotide polymorphisms in various target genes on 
pain sensitivity and/or analgesic dosing requirements22,31. 
Pharmacogenomic approaches offer insight into the genetic variables that can 
affect drug uptake, transport, activation of its target, metabolism, interaction with 
other medications and excretion. The use of pharmacogenomics in patients requiring 
pain management can lead to more efficient opioid selection, dose optimization and 
minimization of ADRs to improve patient outcome32. 
Hence, in the past 15 years, a big effort has been directed to identification of 
genetic factors that may explain inter-individual differences in pain sensitivity and 
analgesic drug dosing requirements31. 
The effect of genotype on the pharmacokinetics and pharmacodynamics of 
analgesic drugs has also been assessed in numerous genetic association studies. Such 
studies have generally been designed to assess the influence of single-nucleotide 
polymorphisms (SNPs) in candidate pain genes encoding receptors and ion channels 
implicated in pain modulation, and/or the effect of genes encoding drug metabolizing 
enzymes and transporters on analgesic drug pharmacokinetics31. 
The “genetic architecture of human pain perception” has been proposed to 
include rare deleterious genetic variants and more common genetic polymorphisms as 
mediators of human pain perception and clinical pain phenotypes. For example, the 
differences between men and women resulting from evolutionary pain-modulation 
processes, which afford women a greater sense of awareness of potential 
environmental threats to offer heightened protection to their offspring33. 
 
4.2. Morphine and analgesia 
 
Opioids are indicated for the treatment of moderate to severe pain. Morphine 
is the main alkaloid of Papaver somniferum and is used in therapeutics as a potent 
analgesic34 to control moderate and severe pain31,32. 
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According to Zhu et al, 2005, human organism is capable to produce morphine. 
Human white blood cells (WBC), specifically polymorphonuclear cells, have the ability 
to synthesize morphine. The WBC also express CYP2D6, enzyme capable of 
synthesizing morphine from tyramine, norlaudanosoline, and codeine. Morphine can 
also be synthesized by another pathway, via L-3,4-dihydroxyphenyllanine (L-DOPA). 
Finally, they showed that WBC release morphine.  These studies provided evidence 
that the synthesis of morphine by various animal tissues is more widespread than 
previously thought, including human immune cells. Moreover, another pathway for 
morphine synthesis exists, via L-DOPA, demonstrating an intersection between DA 
and morphine pathways. WBC can release morphine into the environment to regulate 
themselves and other cells, suggesting involvement in autocrine signaling since these 
cells express the µ3 opiate receptor subtype35. 
Worldwide patterns of opioid consumption differ depending on cultural, 
educational, and economical factors, in addition to characteristics inherent to health 
care infrastructure and accessibility. The top 20 countries with the highest 
consumption of morphine miligram equivalents per capita (in 2008), are listed in figure 
6. In these countries, particularly the United States and Canada, opioids are more 
commonly administered to pregnant and lactating women for the treatment of acute 
pain36. 
 
 
Figure 6 – Global Morphine Consumption, 2008: mg/capita – Top 20 Countries36 (Adapted from Madadi 
et al, 2012) [* Austria uses morphine in treatment of drug dependence.]. 
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Morphine has been widely used to treat severe pain. Besides the classic side 
effects that comes from epidural morphine administering, the most common ADRs are 
pruritus, nausea and vomiting37. The incidence of pruritus after epidural morphine 
ranges from 1% to 90%, nausea from 7% to 60%, and vomiting from 17% to 50%. In 
women receiving epidural morphine to treat post cesarean section pain, 58%-93% 
complained of pruritus and 16%-59% of nausea and vomiting (5%-10%)38. 
Pruritus is a side effect caused by epidural morphine. Besides pruritus there are 
some more side effects, like nausea, vomiting, respiratory depression and difficulty in 
micturition. These undesirable effects, although with low morbidity rate, bring 
discomfort to patients and may prolong hospital stay. Different treatments have been 
proposed to prevent or treat these effects. Naloxone, opioid antagonist drug, would 
be the best choice and can reverse the side effects of morphine. However its use has 
been associated to lower analgesia quality, in addition to undesirable cardiovascular 
effects in some cases. Propofol has also been suggested as therapeutic option, but its 
effectiveness against itching is controversial and cost is high. More recently, 
ondansertron, a serotonin antagonist, is being successfully used to treat cholestasis and 
morphine-induced itching39. 
 Epidural morphine produces better analgesia than intravenous morphine, but it 
way produce more severe pruritus. The exact mechanisms underlying pruritus 
pathophysiology remain poorly understood. However, medullary dorsal horn 
activation may be related to pruritus40, according to a study conducted with 58 
women. 
Pruritus may be generalized but is more likely to be localized to the face, neck, 
or upper chest. Severe pruritus is rare, occurring in only about 1% of patients. On the 
face, it is more common on trigeminal-nerve innervated areas, indicating cerebrospinal 
fluid (CSF) migration and interaction with the nucleus of this nerve, which in turn has 
opioid receptors also present on its nervous roots. This rostral movement of opioids 
toward baseline cisterns helps the access to the trigeminal nucleus. Some other 
mechanisms, suggested for itching, are based on histamine, tachycinine and interleukin 
release, substances which promote itching by themselves, but which have pro-
inflammatory activity, being able to sensitize nervous terminations and lead to itching. 
In addition, 5-HT3 (serotonin) may be an itching regulating substance by directly acting 
on its receptors, mechanism observed in patients with cholestasis37,39. 
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Histamine and compounds release peripheral histamine from mast cells and are 
the primary experimental itch mediators in humans. A specialized itch pathway has 
been identified, with specific mechano-insensitive C. fiber primary afferents and 
spinothalamic projection neurons in lamina I of the dorsal horn, both responding to 
histamine application. However, non-histaminergic pruritic mediators are known (e.x. 
proteases), and antihistamines are ineffective in many pruritogenic diseases and models.  
Although pruritus is now unanimously considered a distinct sensation from pain, 
there are undoubtedly interactions between the two. Conversely, pain inhibition via 
local anesthesia intensifies histamine-induced itch, and pruritus is a common and 
problematic side effect of pain treatment with u-opioid agonists41. However, animal 
studies were the basis for the concept of an “itching center” located below the spinal 
cord and indicating that the trigeminal nucleus would be involved in this mechanism37. 
Serotonin is a powerful pruritic agent in mice, but there are probably important 
differences between rodents and humans in the relative involvement of histamine and 
serotonin in the mediation of pruritus41. 
In the era of opioid therapy, pharmacogenomic studies to guide opioid-based 
analgesic regimens are flourishing. Among the numerous candidate genes that have 
been considered important in opioid response, the CYP family of enzymes, the μ-
opioid receptor gene (OPRM1, p.118 A>G) and the Cathecol-O-methyltransferase 
gene (COMT, p.158Val>Met) have been extensively reviewed. However, most drug 
effects are determined by the interaction of several polymorphisms that influence the 
pharmacokinetics and pharmacodynamics of medications, including inherited 
differences in drug targets (ex. receptors) and drug availability (ex. drug-metabolizing 
enzymes and transporters). This interplay may result in polygenic determinants that 
involve numerous potential combinations of drug-metabolism, drug-transporters and 
drug-receptor genotypes with corresponding drug-response phenotypes yielding a 
wide-range of therapeutic indexes (efficacy/toxicity ratios) for a given drug33. 
 
4.2.1. Opioid metabolism 
 
Opioid metabolism by CYP450 enzymes and enzymes that regulate 
glucuronidation to produce metabolites influence the concentration of drug available at 
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the effect site and therefore its clinical efficacy. Genes encoding enzymes responsible 
for these metabolic pathways exhibit considerable polymorphism resulting in wide 
variability in inter-individual responses to some opioids42. 
The clinical effects of the weaker opioids codeine, dihydrocodeine, tramadol, 
oxycodone, and hydrocodone rely upon the formation of more potent hydroxyl 
metabolites (such as morphine, dihydromorphine, and oxymorphone) by a metabolic 
pathway (Figure 7) mediated via the cytochrome P450 enzyme CYP2D636,42. 
Morphine is further metabolized into morphine-6-glucuronide (M6G), morphine-
3-glucuronide (M3G) and normorphine; both morphine and M6G display opioid 
activity33. Additionally, in a smaller extent, morphine is also metabolized by CYP2D635. 
Opioids have been widely used within the fields of anesthesia and acute and 
chronic pain for many years, and their use is characterized by large inter-patient 
variations in dosage requirements. Although many factors can influence pain perception 
and sensitivity, some of the variable clinical response to opioids can be explained by 
genetic heterogeneity in factors affecting both the pharmacodynamic and the 
pharmacokinetic behavior of these drugs42. 
 
  
Figure 7 – Major metabolic pathways of morphine in humans with the isoenzymes involved33,34 (Adapted 
from Maurer et al, 2006 and Vuilleumier, 2012). 
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5. Detoxification metabolism and xenobiotics 
 
The human body is exposed to a high number of xenobiotics during lifetime, 
including a variety of pharmaceutical drugs and food components, and has developed 
complex enzymatic mechanisms to detoxify these substances (Figure 8). These 
mechanisms exhibit significant individual variability, and are affected by environment, 
lifestyle, and genetic influences43.  
Therefore, human body is capable of managing exposure to toxic substances, 
using a complex systems of detoxification enzymes that minimize the potential damage 
of xenobiotics. 
The hypothesis that xenobiotics consumed by animals are transformed to water-
soluble substances and excreted through the urine was first put forth in the late 18th 
century. Later, on 1947, R.T. Williams defined the field of detoxification in his 
monograph “Detoxification Mechanisms”. This biochemist proposed that these non-
reactive compounds could be biotransformed in two phases: functionalization, which 
uses oxygen to form a reactive site, and conjugation, which results in addition of a 
water-soluble group to the reactive site44. 
 
Figure 8 – Liver detoxification pathways in the metabolism of xenobiotics and endogenous components43 
(Adapted from Liska, 1998). 
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These two steps, functionalization and conjugation, are termed Phase I and Phase 
II detoxification, respectively: 
- The Phase I system: composed mainly of cytochrome P450 (CYP450) 
supergene family of enzymes. It is generally the first enzymatic defense against 
foreign compounds and endobiotics also, including end products of metabolism 
and bacterial endotoxins. Most drugs are metabolized trough Phase I 
biotransformation (Table 1). In a typical Phase I reaction, a CYP450 enzyme 
uses oxygen and NADH as a cofactor to add a reactive group, such as a 
hydroxyl radical. As a consequence of this step in detoxification, reactive 
molecules, which may be more toxic than the original molecule, are produced. 
If these reactive molecules are not further metabolized by Phase II conjugation, 
they may cause damage to lipids proteins, RNA, and DNA, within the cell. In 
table 1, the common genetic variants in Phase I drug metabolizing enzymes and 
some selected drugs substrates, are presented. 
 
- The Phase II system: Phase II conjugation reactions generally follow Phase I 
activation, resulting in a metabolite that has been transformed into a water-
soluble compound that can be excreted through urine, bile or stool. Several 
types of conjugation reactions are present in the body, including 
glucuronidation, sulfation and glutathione and amino acid conjugation43,45. 
However, there are xenobiotics and endobiotics like hormones, that are 
metabolized through this phase first. 
 
 
Table 1 – Overview of common genetic variants in Phase I drug metabolising enzymes45 (Adapted from Pinto et 
al, 2011). 
 
CYP2D6 
Important 
Variants 
Variations 
Consequence of 
Variation 
 
Effect on 
Enzyme 
Activity 
 
Some selected 
drugs acting as 
substrates 
CYP2D6*2 
c.1457C>G 
(rs1135840) 
Silent mutation Normal activity 
 
Amitriptyline 
Atomoxetine 
Carvedilol 
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Important 
Variants 
Variations 
Consequence of 
Variation 
 
Effect on 
Enzyme 
Activity 
 
Some selected 
drugs acting as 
substrates 
CYP2D6*3 
c.775delA 
(rs35742686) 
Frame shift 
mutation, 
premature codon 
stop 
Absence activity 
Chlorpromazine 
Citalopram 
Clomipramine 
Clozapine 
Codeine 
Debrisoquine 
Dextromethorph
an 
Flecainide 
Fluoxetine 
Gefitinib 
Haloperidol 
Imipramine 
Imaprotiline 
Metoprolol 
Morphine 
Nortriptyline 
Paroxetine 
Risperidone 
Tamoxifen 
Thioridazine 
Timolol 
Tramadol 
CYP2D6*4 
c.506-1G>A 
(rs3892097) 
Splicing defect Absence activity 
CYP2D6*5 
CYP2D6 
deleted 
Whole gene 
deletion 
Absence activity 
CYP2D6*6 
c.454DelT 
(rs5030655) 
Frame shift 
mutation 
Absence activity 
CYP2D6*10 
c.100C>T 
(rs1065852) 
p.Pro34Ser Reduced activity 
CYP2D6*17 
c.320 C>T 
(rs28371706) 
p.Thr107Ile Reduced activity 
CYP2D6*41 
c.985+39G>A 
(rs28371725) 
Splicing defect Reduced activity 
 
 
 
6. CYP450 enzymes 
 
The CYP450 enzymes comprise a ubiquitous and very large superfamily of 
hemeprotein monooxygenases that metabolize physiologically important compounds 
vital to life of most organisms from protists to plants and mammals. They catabolize 
and detoxify not only xenobiotics compounds, including drugs, procarcinogens and 
carcinogens, but also participate in synthesis of steroid hormones, cholestrol, bile acids 
and degradation of endogenous compounds, namely  fatty acids and steroids46. 
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It is well known that polymorphisms in the CYP genes affect the activities and or 
specificities of the encoded enzymes, which causes differences in the response to drugs 
that are substrates for these enzymes47. 
Furthermore, CYP450 is also involved in the maternal metabolism of pregnant 
women. The placenta contains CYP450 enzymes that are capable of metabolizing 
xenobiotics and endotoxins. N-acetyltransferase, glutathione transferase, and 
sulphating enzymes are also present. These enzymes can change the activity of drugs as 
they cross through the fetus. As more drugs are metabolized within the placenta, two 
effects may occur: the drug is metabolized to an active or an inactive form. During the 
first trimester, the fetal liver is not able to metabolize drugs using CYP450 enzymes. 
Once fetal liver development is complete, the fetus has the same enzymes, with the 
exception of CYP3A4, which is expressed only later in life48. It is important to mention 
that the majority of CYP enzymes are inducible, being expressed in the presence of the 
substrate. 
However, changes in maternal metabolic function during pregnancy are largely 
unknown and the activity of the cytochrome P450 enzymes needs further study to 
effectively predict the metabolic rate of metabolized drugs by the liver. Renal function 
is gradually elevated, leading to increased elimination of water-soluble drugs and 
metabolites48. 
The major families responsible for the oxidative metabolism of drugs and 
environmental chemicals are CYP1, CYP2 and CYP3 (Figure 9). 
 
Figure 9 – The most important CYPs of Cytochrome P45043 (Adapted from Liska, 1998). 
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6.1. CYP2D6 
 
The CYP2D6, also known as debrisoquine/sparteine hydroxylase, is one of the 
most important and perhaps the most extensively studied drug metabolizing enzyme in 
humans49. It is responsible for the metabolism of 25-30% of all drugs on the market20,50,51 
such as antidepressants, neuroleptics, antiarrhythmics, analgesics, steroids, antiemetics, 
anticancer drugs and other xenobiotics52,53. 
Moreover, CYP2D6 substrates are lipophilic bases with a protonable nitrogen 
atom. The hydroxylation reaction takes place at a distance of 5 or 7 Å from the nitrogen 
atom. CYP2D6 has a very high affinity for alkaloids20.  
This enzyme, with 497 aminoacids, is encoded by the CYP2D6 gene, which was 
the first P450 gene to be characterized at the molecular level and has a high clinical 
importance20, because influence pharmacokinetic rate and drug effects34. 
The CYP2D6 gene is located in chromosome 22, together with the two 
pseudogenes CYP2D7P and CYP2D8P, which are localized in tandem20,47,54 (Figure 10). 
 
 
Figure 10 – The CYP2D6 gene and most common polymorphisms (UTR=untranslated region)55 (Adapted 
from Zhou et al, 2009). 
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Tyramine Dopamine 
CYP2D6 
Figure 11 – Synthesis of dopamine by CYP2D635 (Adapted from Zhu et al, 2005). 
Approximately 100 different alleles (Allele Nomenclature Database) of the 
CYP2D6 gene have been identified, and their frequency varies between ethnic 
populations56. The enzymatic activities in individuals carrying these allelic differences 
vary from total absence to different degrees of ultrarapid metabolism, which causes 
considerable variability in the response to certain drugs treatments31,47. In addition, the 
UM phenotype is one explanatory factor for lack of response to antidepressants and 
decreased levels of several drugs which are CYP2D6 substrates, such as tramadol, 
antiemetics, venlafaxine, morphine and metoprolol are evident. 
This gene is also expressed in small amounts in other tissues such as brain, 
especially in the midbrain, gastrointestinal tract and lungs45,57.  
It is very interesting that CYP2D6 polymorphisms have some relationship with 
personality traits (psychic anxiety, psychasthaenia, inhibition of aggression, and 
socialization) and so that is involved in the metabolism of endogenous psychoactive 
substrates or products, participating in the metabolism of some neuroactive amine and a 
possible influence on gender-related factors58. In humans, it is known that tyramine is 
one of the trace amines and is present in the brain, especially in the basal ganglia or 
limbic systems, which are thought to be related to personality and emotion59. Recent in 
vivo and in vitro animal studies support CYP2D6 involvement in the biotransformation of 
endogenous substances, such as tyramine to dopamine, progesterone to its 
hydroxylated derivates and 5-methoxytryptamine (5-MT) to serotonin (5HT) (figure 
11)58,60,61. 
 
 
 
Serotonin is implicated in the maintenance of psychological balance, and defects 
in its production are for example responsible for depression, impulsivity, obsessionality, 
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aggression, psychomotor inhibition, analgesia, hallucinations, eating disorders, attention 
and mood. In addiction, serotonin is converted into melatonin, and these two amines 
control the wake-sleep cycle62,63. 
Additionally, individuals with null CYP2D6 activity (Poor Metabolizers (PMs)) 
may present a potential reduction in regeneration of serotonin, as well as a slightly 
elevated dopamine tone due to the inverse correlation between the serotonin and 
dopamine systems, which may affect psychological process. Dopamine and serotonine 
are two key players in pain control and response60. 
 
 
6.1.1. CYP2D6 alleles 
 
The functional impact of the various CYP2D6 alleles can be classified into three 
groups: alleles resulting in increased activity; alleles resulting in decreased or loss of 
activity and alleles with normal or activity (Table 2). 
 
Table 2 – Variant alleles of CYP2D6 predicted activity and the metabolic profiles in correlation with genetic 
variants64 (Adapted from The Human Cytochrome P450 (CYP) Allele Nomenclature Committee). 
 
Allele Variant 
 
Consequence 
 
Predicted  
Activity 
 
Phenotypes 
*1 
2 functional genes Normal EM 
*2 
*3 lacking functional 
enzyme due to 
defective or deleted 
genes 
Null PM 
*4 
*5 
*6 
*10 1 functional and 1 
defective allele but 
may also carry 2 
partially defective 
alleles 
Decrease 
 
IM 
*17 
*41 
(*1 or *2) x N 
more than 2 active 
genes 
Increase UM 
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Most of the CYP2D6 allelic variants are quite rare. Important variants in 
Caucasian population include CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, 
CYP2D6*10, CYP2D6*17 and CYP2D6*4164. 
 
 
6.1.1.1. CYP2D6*1 
 
The *1 allele corresponds to the wild-type variant. So, it is the more frequent in 
the general population, and corresponds to normal enzyme activity55,65. 
 
 
6.1.1.2. CYP2D6*2  
 
The *2 allele has been described as having no functional impact in the metabolic 
profile. Enzyme activity is similar to that of the wild-type variant. The most relevant 
SNPs associated to this allele are c.900C>T transition in exon 6, leading to 
p.Arg296Cys change, and c.1457C>G variation in exon 9, resulting in p. Thr48Ser 
substitution55.  
 
 
6.1.1.3. CYP2D6*3 
 
This variant contains a deletion of “A” in position 2,549 of the gene, in exon 5 
(c.775delA), leading to a disrupted reading frame. So, this fact would readily explain the 
absence of CYP2D6 protein and function in PMs due to premature termination of 
protein synthesis55.  
 
 
6.1.1.4. CYP2D6*4 
 
The *4 allele is the most common variant allele in Caucasians (allele frequency 
is 21%). This variant is characterized by one of seven SNPs: c.100C>T in exon 1; 
c.271C>A, c.281A>G and c.305C>G in exon 2; c.406G>C in exon 3; c.506-1G>A in 
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intron 3; c.1455 G>C in exon 9, resulting in, respectively, 4 aminoacid substitutions 
(p.Pro34Ser; p.Leu91Met; p.His94Arg; p.Ser486Thr), one silent variation and one 
splicing defect contributing to a null debrisoquine hydroxylation in vivo66. 
 
 
6.1.1.5. CYP2D6*5 
 
The CYP2D6*5 allele, is characterized by a deletion of the entire gene. The 
homozygous carriers totally lack metabolic activity due to total absence of CYP2D6 
protein in liver47. It is present in 4% of Caucasian populations and it is considered to 
result from an unequal crossover between two chromatids, while repeated unequal 
crossover events of chromatids will lead to gene multiplication55. 
 
 
6.1.1.6. CYP2D6*6 
 
The *6 allele is defined by c.454delT SNP allele in exon 3, a nucleotide deletion 
that causes a frame shift of one aminoacid (p.Trp152Glyfs) leading to a total loss of 
enzyme activity55. 
 
 
6.1.1.7. CYP2D6*10 
 
CYP2D6*10 is probably the most common CYP2D6 allele worldwide20. This 
allele has a c.100C>T SNP causing p.Pro34Ser substitution in the proline-rich region 
near the NH2 terminal of the protein, which is highly conserved among CYPs of 
different species and is associated with a low in vivo sparteine clearance. The residue 
P34 may act as a hinge between the hydrophobic membrane anchor and the heme-
binding region of the enzyme. The c.100C>T SNP resulted in an unstable protein with 
significantly reduction of enzyme activity67. 
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6.1.1.8. CYP2D6*17 
 
CYP2D7*17 is generally considered to be a reduced function allele68, and this is 
the major variant CYP2D6 allele among Africans20. This variant has been classified 
according to the presence of four SNPs: c.320C>T in exon 2; c.406G>C in exon 3 (a 
silent SNP); c.884C>T in exon 6; and c.1455G>C in exon 9. Compared with 
CYP2D6*2, CYP2D6*17, it contains one more substitution (p.Thr107Ile). This change 
occurs in a region of the β’-helix that is conserved across species, and residue 107 may 
be involved in substrate recognition. The *17 allele has been associated with decreased 
debrisoquine hydroxylation in vivo55.  
 
 
6.1.1.9. CYP2D6*41 
 
The *41 allele has been described as having reduced function. This variant is 
characterized by one of three main SNPs: c. 886C>A in exon 6; c.1457G>C in exon 9 
and c.985+39G>A in intron 6, resulting respectively in one missense substitution, one 
splicing defect and one aminoacid substitution (p.Ser486Thr)69.  
 
6.1.1.10. Copy Number Variations (CNVs) 
 
The CNVs are DNA segments at 1kb or larger with a variable number of 
copies in comparison with a reference genome. Besides, they can have dramatic 
phenotypic consequences as a result of altering gene dosage, disrupting coding 
sequences, or perturbing long-range gene regulation52.  
By the invention of new techniques that rapidly allow the analysis of full 
genomic occurrence of CNVs using Single Nucleotide Polymorphisms (SNP) 
genotyping arrays and clone-based comparative genomic hybridization, it was recently 
found that this is a very common phenomenon in the human genome. A total number 
of 1447 CNVs had been identified in the human genome, covering 360Mb (12% of the 
genome)52.  
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Focus on enzymes involved in xenobiotic metabolism reveals that there are 
several well-known examples of CNV, such as CYP2A6 and CYP2D6. Initially CNVs 
were thought to be very rare events but an increased number of functionally active 
genes was first described for CYP2D6 and at the moment the maximum identified was 
13 gene copies. CYP2D6 gene can suffer duplications and even multiplications being 
more frequent in Africans than in Asians and north Caucasians. On the other hand, 
CNVs may also be deleted (CYP2D6*5) at a relatively high frequency in at least one 
ethnic group. Because of that, CYP2D6 CNVs affect drug metabolism to a large extent, 
but do not crucially affect disease susceptibility, so a high frequency of CNVs is 
permitted52. 
 
 
6.1.2. Activity Score (AS) 
 
The activity score is based on extensive genotype/phenotype comparisons and 
measurements of enzymatic activity and is used to approximate the phenotype for a 
given genotype in an individual. The scoring system, based on enzymatic activity, assigns 
a value of one for normal functioning alleles, and values of 0 or 0.5 for null and reduced 
functioning alleles, respectively. Duplicated alleles have their values counted twice, as 
determined to be valid in the derivation of the activity score. Phenotypic extensive 
metabolizers are classified as “high metabolizers” if their activity score is greater than 
1.5. Therefore, the sum of the individual allele values formed the AS70 and it is used to 
predict metabolic profile. 
 
6.1.3. Metabolic profiles of CYP2D6 
 
The high molecular multiplicity of CYP2D6 gene, results in four major drug 
oxidation phenotypes which were termed poor (PM), intermediate (IM), extensive 
(EM) and ultrarapid metabolizers (UM) (Table 3). These phenotypes are associated 
with variable drug response, including ADRs, due to increased drug plasma 
concentration in PMs or therapeutic failure as a result of very rapid drug degradation 
in Ums71. 
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Furthermore, the distribution of PM, IM, EM and UM of CYP2D6 varies among 
ethnic groups72. 
 
6.1.3.1. Poor Metabolizer 
 
This phenotype is characterized by lacking functional enzyme due to defective 
or deleted genes52 and so that, PM individuals have no detectable enzymatic activity32. 
This condition can lead to an excessive or prolonged therapeutic effect or drug-related 
toxicity after a normal dose, conferring a genetic predisposition to drug-induced 
adverse effects. Moreover, in case of compounds that need to be activated, the PM 
condition may result in association with decreased response73. In Portugal, the 
frequency of PMs is 6.3%56. 
 
6.1.3.2. Intermediate Metabolizer 
 
The IMs phenotypes located between the PM and EM, and are usually carrying 1 
functional and 1 defective allele but may also carry 2 partially defective alleles52. So, IM-
classified individuals show decreased enzymatic activity27 In Portugal, the frequency of 
IMs is 32.7%56. 
 
6.1.3.3. Extensive Metabolizer 
 
The EMs carry 2 functional genes52 and they are the most common worldwide 
and also in the Portuguese population, with a frequency of 56.3%56. Therefore EM-
classified individuals are characteristic of the normal population and have a wild-type 
copy of the gene32. 
 
6.1.3.4. Ultrarapid Metabolizer 
 
This phenotype is characterized by the presence of more than two active 
CYP2D6 alleles presenting a higher metabolic activity52,74. Thereby, UM-classified 
individuals typically contain multiple copies of a gene, which results in an increase in 
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drug metabolism2. UMs may have a hydroxylation capacity more than 100 times higher 
than PMs60. In Portugal, the frequency of IMs is 4.7%56. 
 
Table 3 – CY2D6 variability56,75 (Adapted from Albuquerque et al., 2013 and Prado et al., 2009). 
 
§ Portuguese caucasian population; N = number of alleles; PM = Poor Metabolizer; IM = Intermediate 
Metabolizer; EM = Extensive Metabolizer; UM = Ultrarapid Metabolizer. 
 
 
 
Pain perception is one of the most complex quantifiable traits because it 
encompasses several phenotypes involving the peripheral and central nervous systems, 
and as a complex trait it is expected to have a polygenic nature shaped by 
environmental factors such as trauma, lifestyle, and stress. In addition, an important 
characteristic in determining the pain phenotype is the wide interindividual 
pharmacologic range in response to drugs. Therefore, not surprisingly, translating 
pharmacogenetics to clinical practice has been particularly challenging in the context of 
pain, due to the complexity of this multifaceted phenotype and the overall subjective 
nature of pain perception and response to analgesia. Yet, with a growing body of 
evidence demonstrating a strong association between severe acute pain and the risk 
for persistent pain, identifying individuals with an increased vulnerability to pain, 
including genetic factors, may allow to substantially improve clinical outcomes33.  
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It is reasonable to think, from the text above, that CYP2D6 metabolic profile 
may influence pain and this is the novel hypothesis that has been explored in the 
present work. 
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7. Clinical impact 
 
Estimates reveal that between 25-30% of all drugs in clinical use are metabolized 
at least in part by CYP2D6. Either they are metabolic inactivate, substrate or metabolic 
inducers, their clinical efficacy, safety and response will change drastically, according to 
CYP2D6 polymorphisms, leading to heterogeneous ADRs76.  
Individuals with multiple gene copies will metabolize drugs more rapidly and 
therapeutic plasma levels will not be achieved at ordinary drug dosages. On the other 
hand, individuals lacking functional CYP2D6 genes metabolize selective CYP2D6 
substrates at a lower rate, and the risk for adverse drug reactions is higher20. 
For example, the pro-drug codeine is converted to morphine in the liver by the 
CYP2D6 enzyme. There are many genetic variations of CYP2D6, which affect the 
extent of this conversion in individuals. This leads to differences in the plasma levels of 
morphine and different levels of pain relief.  
So that, the individuals with CYP2D6 PM profile have no analgesic effect due to 
extremely low morphine plasma concentrations. Conversely, increased effectiveness of 
codeine with sometimes life-threatening opioid intoxication9 was observed in patients 
with multiple CYP2D6 gene copies, but also in neonates whose breastfeeding mothers 
were genetic CYP2D6 UMs, consistent with higher rates of conversion to morphine in 
patients with UM phenotype76. 
Accordingly, due to the importance of CYP2D6 gene, it is relevant to characterize 
different populations so that could become a routine as part of an “individualized” drug 
treatment54. 
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Abstract 
 
Objectives: Pharmacogenetic CYP2D6 analysis, in 55 Portuguese Caucasian adult 
parturients undergoing analgesia with morphine after cesarean section, including the 
association with pain scoring and pruritus. 
Study Design: DNA was extracted from peripheral blood of 53 Portuguese 
Caucasian adult parturients. Genetic analysis included allelic discrimination (CYP2D6*1, 
*2, *3, *4, *5, *6, *10, *17 and *41) and copy number determination with TaqMan 
probes by Real-Time PCR. Allele duplications were confirmed by long PCR and PCR-
Restriction Fragment Length Polymorphism (RFLP). Metabolic profiles were predicted 
based o genetic data and activity scores. The genotypes and metabolic profiles were 
correlated with pain scores and the disclosure of the ADR pruritus. The statistical 
analysis was performed by χ2 test and results are considered statistically significant if 
p<0.05. 
Results: The percentage of Poor Metabolizer, Intermediate Metabolizer, 
Extensive Metabolizer and Ultrarapid Metabolizer found are 9%, 38%, 46% and 7%, 
respectively. As expected, EM and IM are the most frequent metabolic profiles, as in 
Caucasian population. The results reveal a positive association with pain to alleles *2, 
*4 and *10 and with pruritus to alleles *2 and *10.  
Conclusions: A positive association was found between CYP2D6 reduce 
activity and increased pain. It can be hypothesized that if CYP2D6 activity is reduced, 
tyramine metabolism is decreased, resulting in reduced formation of endogenous 
dopamine. Consequently the activation of signal transduction pathway that controls 
neuronal pain and analgesic effect may be reduced, leading to an increase of pain after 
cesarean.  
A positive association was also found between CYP2D6 reduced activity and 
pruritus. However the exact mechanism of neuroaxial opioid-induced pruritus remains 
unclear. 
 
Keywords: CYP2D6; Pain; Pharmacogenetics; Cesarean section; Labor analgesia.  
 
 Rosa Quinta, 2014  Page 41 
1. Introduction 
 
Pain is defined as a dynamic and complex process that involves actions at multiple 
sites ranging from the peripheral nociceptor to the genome of cells within the central 
nervous system to the patient’s psychosocial milieu32,77,78. Individual variability to pain 
response and treatment is influenced by multiple factors including sensitivity to pain, 
neurochemical factors, age, gender, ethnicity, smoking, alcohol drinking, disease 
process and genetics.  
A significant number of women experience moderate or severe acute post-
partum pain after vaginal and cesarean deliveries. Furthermore, 10-15% of women 
suffer chronic persistent pain after cesarean section79. Therefore, are the mainstay for 
treatment of pain80 and are used to provide analgesia with substantial interindividual 
variability in efficacy81. 
Morphine is the foremost opioid used for pain relief in the opiate family and has 
a high affinity and intrinsic activity for the miu-opioid receptor82. This drug is 
metabolized into morphine-6-glucuronide (M6G), normorphine and morphine-3-
glucuronide; both morphine and M6G display opioid activity33,34,52,83.  
In current clinical practice, morphine is used for the management of acute and 
chronic pain and in analgesia of parturients undergoing cesarean. This opioid induced 
vasodilatory response and appeared to be mediated or modulated by both opioid 
receptor and histamine-receptor-sensitive pathways84. 
Over the past two decades, epidural and spinal opioids management to provide 
labor analgesia and treat postoperative pain have been increased82. Morphine is the 
main alkaloid of Papaver somniferum and is used as a potent therapeutic analgesic. It is 
also an opioid agonist, highly specific for miu-receptors located in the central nervous 
system and smooth muscle.  
In pregnancy, morphine is used to alleviate pain associated with parturition82. 
This opioid activates the pathway mediate by opioids receptor in midbrain and 
terminates in the nucleus accumbens to end GABA inhibition of dopaminergic neurons, 
causing an increase in dopamine release, essential for pain control85.  
However, there is a large inter-individual variability in efficacy of and tolerance to 
opioids, namely onset of side effects like pruritus, nausea and vomiting. 
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Understanding the metabolism of opioid analgesics is important for studying of 
different sensitivities to analgesic therapy. The diversity of responses is due to several 
factors, mentioned above. Differences in the cytochrome P450 (CYP450) metabolizing 
capacity, caused by genetic polymorphisms, have a huge impact in individual response 
and in the development of adverse effects to drug therapy20. 
The CYP450 system is a superfamily coded by, so far known, 56 functional 
genes86, including the CYP2D6 that is located at the chromosome 22q13.187 and 
consists of nine exons with an open reading frame of 1,491 base pairs encoding 497 
amino acids55. Besides, this highly polymorphic gene is responsible for the metabolism 
of about 25% of all drugs on the market and its polymorphisms significantly affect the 
metabolism of about 50% of the drugs31,56,71,88. 
 The CYP2D6 enzyme has been found in liver, heart and brain tissues and is also 
responsible for the oxidation metabolism of various drugs and endogenous substances, 
such as the tyramine and 5-hydroxytryptophan as precursors of dopamine and 
serotonin, respectively in brain 62,76.  
Currently, there are more than 100 different allelic CYP2D6 gene variants 
described to date on the Human Cytochrome P450 Allele Nomenclature Database and 
the number of alleles is still growing. In table 4, some examples of these alleles, 
influencing metabolic profiles, are described. 
Because the high variability of CYP2D6 gene, the enzyme activity can be classified 
as resulting in four major phenotypes that are described in table 464. Note that the 
Ultra Metabolizer (UM) has more than 2 active functional genes89. 
Table 4 – Allelic variant and predicted metabolic profile. 
 
Allele 
 
*2 
 
*3 
 
*4 
 
*6 
 
*10 
 
*17 
 
*41 
 
Predicted 
activity 
 
Normal 
 
Null 
 
Decreased 
 
Phenotypes 
 
EM 
 
PM 
 
IM 
EM (Extensive Metabolizer), PM (Poor Metabolizer), IM (Intermediate Metabolizer). 
 
 Rosa Quinta, 2014  Page 43 
However, populations with different ethnic origins, the pattern of CYP2D6 
polymorphisms and phenotype differs dramatically. The frequency of CYP2D6 UMs, 
EMs, IMs and PMs is approximately 3–5%, 70–80%, 10–17% and 5–10%, respectively, in 
Caucasians55.  
The clinical relevance of CYP2D6 genotyping to predict analgesic outcomes is 
still relatively unknown. In a recent pilot study, the relationship between CYP2D6 
genotype, post-cesarean pains, codeine consumption, and side effects were evaluated. 
The two extremes in CYP2D6 genotypes seemed to predict pain response and/or 
adverse effects33. 
The present study aimed to analyze the CYP2D6 genetic variations and copy 
number for predicting metabolic profiles in a population of Portuguese Caucasian adult 
parturients submitted to analgesia with morphine after cesarean section. Addictionally, 
an association analysis of CYP2D6*1,*2,*3,*4,*5,*6,*10, *17 and *41 variants that 
modulating the activity of the enzyme and the efficacy of pain relief and emerging of 
pruritus, was also performed. 
 
2. Material and Methods 
 
Subjects  
Blood samples were collected from 55 Portuguese Caucasian adult parturients 
followed at Centro Hospitalar e Universitário de Coimbra (mean age 32±4, range was 21–
42 years). 
All women were treated with 2.5mg of morphine for analgesia after cesarean 
section. 
After surgery, pain, pruritus, nausea and vomiting were evaluated. To classify 
pain, was used an increasing scale of 0 to 10, was used in which 0 is absence of pain 
and 10 is the worst pain possible. For pruritus, it was used a 3 point scale, were 
0=none, 1=mild, 2=moderate and 3=severe; nausea and vomiting was evaluated as 
“presence” or “absence”. In terms of calculations, it was considered pain less or equal 
to 3 and more than 3. For pruritus, it was considered only the presence or the 
absence. The first score of pain and pruritus was measured immediately before 
administration of morphine, by epidural, and reassessment was performed after 4, 8 
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and 12 hours. Every woman was continuously monitored in the first 12 hours and 
hemodynamic parameter settings (pulse oximetry, respiratory frequency, pain scores, 
nausea, vomiting, pruritus, respiratory depression, urinary retention and level of 
consciousness) were evaluated. 
This study had the approval of the University Hospitals of Coimbra Ethics 
Committee, following the Tenets of Helsinki Declaration, and informed consent was 
obtained from all participants.  
 
Inclusion Criteria 
Parturients older than 18 years; single or multiple pregnancies; cesarean section 
with regional anesthesia and American Society of Anesthesiologists (ASA) I/II. 
 
Exclusion Criteria 
Parturients who presented severe or chronic cardiovascular disease caused by 
pregnancy; patients with history of opioids consumption and pruritus during pregnancy; 
patients with allergy to local anesthetics or opioids and with contraindication for 
regional anesthesia. 
 
DNA Extraction 
The DNA used was extracted from lymphocytes of peripheral blood, using a 
standard phenol-chloroform method, followed by ethanol precipitation. Extracted 
DNA samples were stored at 4ºC before use. The DNA concentration was 
determined by measuring the optical density at 260nm and quality was checked by 
calculation of optical densities ration at 260/280nm (NanoDrop, Thermo Fisher 
Scientific, Inc., Wilmington, USA). 
 
CYP2D6 Genotyping by TaqMan Drug Metabolism Assays 
All subjects were genotyped for *2 (rs1135840, c.1457C>G), *3 (rs35742686, 
c.775delA), *4 (rs3892097, c.506-1G>A), *6 (rs5030655, c.454DelT), *10 (rs1065852, 
c.100C>T) *17 (rs28371706, c.320 C>T) and *41 (rs28371725, c.985+39G>A) alleles, 
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using TaqMan Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, 
CA, USA). These SNPs allow to determine the CYP2D6 alleles *1, *2, *3, *4, *5, *6, 
*10, *17 and *41 and were selected according to its predicted effect on metabolic 
activity: CYP2D6*1/*2 – normal; CYP2D6*3/*4/*5/*6 – null; CYP2D6*10/*17/*41 – 
decreased. 
Genetic analysis were performed as previously described56. 
 
CYP2D6 Copy Number Analysis 
CYP2D6 copy number variations were evaluated according to the standard 
procedure of the CEIBA consortium for the study of Population Pharmacogenetics in 
Iberoamerican Populations using TaqMan Copy Number Assay (Applied Biosystems, 
Foster City, CA, USA), as previously described56.  
Samples were run on Applied Biosystems 7500 Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA).  
All samples were examined in triplicate and the average copy number values 
were determined, only for the samples presenting assay confidence above 95%. Data 
were analyzing using CopyCaller v.2.0 software version 2.0 (Applied Biosystems). 
Whenever there was only one CYP2D6 copy, due to deletion of the entire 
CYP2D6 gene, the sample was characterized as CYP2D6*590. 
For detection of the CYP2D6*1, *2, *4 or *10 duplication alleles, DNA samples 
were analyzed by PCR and PCR-RFLP, as previously reported44. 
 
CYP2D6 genotype and theoretically predicted metabolic groups 
The relationship between CYP2D6 genotype and theoretically predicted 
metabolic groups was evaluated assigning a value concerning each variant CYP2D6 
allele, based on the “activity score” system, according to the strategy described 
previously56,68,72. The activity score is used to approximate the phenotype for a given 
genotype in an individual70. For the wild-type alleles (*1 and *2) the scoring system 
assigned a value of 1, whereas for the null variant alleles (*3, *4, *4xN, *5 and *6) it 
was considered the value of 0; for the decreased variant alleles (*10, *10xN, *17 and 
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*41) it was assigned the score of 0.5 for each active gene; the multiplication 
CYP2D6*1xN or *2xN alleles were scored with 2 points. 
 
Statistical Analysis 
Statistical analysis was performed with χ2 or Fisher’s exact tests, using 
contingency tables with software GraphPad Prism 5 (GraphPad Software , San Diego, 
CA, USA)91. A p<0.05 was considered as statistically significant. 
For the calculation of adequate population size needed for this work, we have 
used the with a confidence level of 94% [103].  
For the calculation of adequate population size needed for this work, according 
to the Portuguese population CENSUS95  we have used software Raosoft® Sample 
size calculator (Raosoft, Inc., WA, USA)92, with a confidence level of 89.15%. 
A minimum of 55 individuals were required for this study, taking into account the 
Portuguese population size (~10 million). The lower and upper limits of the 89% CI, 
for the proportions obtained in genotype determination, were calculated with the 
software VassarStats© (NY, USA)93. 
 
Enzyme hidroxylation capacity groups 
Theoretical enzyme hydroxylation capacity prediction was based on genotype 
and was divided in four categories, as previously described56 UM (more than 2 active 
alleles), EM (2 active alleles), IM (1 active allele) and PM (zero active alleles). 
Functionality of alleles was determined according to data available at the CYP2D6 Allele 
Nomenclature Database64. 
 
 Rosa Quinta, 2014  Page 47 
3. Results 
 
CYP2D6 genotype frequencies and copy number determination 
All the CYP2D6 allelic frequencies of the in the studied population (Table 5) are 
in accordance to those predicted by Hardy-Weinberg law, with exception of the 
CYP2D6*17 and CYP2D6*41 allele variant, possibly due to the scarcity of these rare 
variants in this population, which can cause deviations to the Hardy-Weinberg 
equilibrium. The percentage of individuals with no CYP2D6 active alleles is 9.1% and 
with multiple active copies is 7.2% (Table 5). 
 
Table 5 – Frequencies of CYP2D6 genotypes among a Portuguese Caucasian adult parturients. 
Genotype Active Genes 
Activity 
Score 
n Frequency 95% CI 
*1/*1 2 2 16 0.291 0.187 - 0.421 
*1/*2 2 2 1 0.018 0.003 - 0.096 
*1/*4 1 1 13 0.236 0.143 - 0.363 
*1/*5 1 1 1 0.018 0.003 - 0.096 
*1/*6 1 1 1 0.018 0.003 - 0.096 
*1/*41 2 1.5 4 0.073 0.028 – 0.172 
*1x2/*1 >2 >2 2 0.036 0.010 - 0.123 
*1x3/*1 >2 >2 2 0.036 0.010 - 0.123 
*2x2/*4 2 2 1 0.018 0.003 - 0.096 
*2/*2 2 2 3 0.055 0.018 – 0.148 
*3/*4 0 0 1 0.018 0.003 - 0.096 
*4/*10 1 0.5 1 0.018 0.003 - 0.096 
*4/*17 1 0.5 1 0.018 0.003 – 0.096 
*4/*4 0 0 4 0.073 0.028 - 0.172 
*4/*41 1 0.5 1 0.018 0.028 – 0.172 
*41/*41 1 1 3 0.055 0.018 – 0.148 
Abbreviations: CI, confidence interval; n, number of subjects 
 
 
CYP2D6 allelic variants frequencies 
The most frequent alleles was wild type (wt) allele *1 (0.509). The frequency of 
allele *2 and *4 are 0.064 and 0.236, respectively. The alleles *3, *5, *6 *10 and *17 
were found with the same frequencies (0.009) and allele *41 was found with frequency 
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of 0.100. The duplicated alleles were observed with a frequency of 0.045 for *1xN or 
for *2xN (Table 6). 
 
Table 6 – Frequencies of CYP2D6 variant alleles among the Portuguese Caucasian adult parturients. 
  
  
Pregnant Women (n=55) 
Frequency n 95% CI 
wt (*1) 0.509 56 0.417 - 0.600 
*2 0.064 7 0.031 - 0.125 
*3 0.009 1 0.001 - 0.049 
*4 0.236 26 0.166 - 0.323 
*5 0.009 1 0.001 - 0.049 
*6 0.009 1 0.001 - 0.049 
*10 0.009 1 0.001 - 0.049 
*17 0.009 1 0.001 - 0.049 
*41 0.100 11 0.056 - 0.170 
Multiplications: 
(*1 or *2) x N 
0.045 5 0.019 - 0.102 
Abbreviations: CI, confidence interval; n, number of subjects; N, number of alleles; wt, wild 
type. 
 
Metabolic Profiles 
We have determined the frequencies of theoretical metabolic profiles in a 
Portuguese population of Caucasian adult parturients (Figure 12). The EM and IM 
profiles are more frequent in this population, as expected from other studies55, 46% 
and 38%, respectively; the percentages of PM and UM are 9% and 7%, respectively. As 
we expected by comparison with population of women with fertile age (until 47 years 
old), it is considered statistically not significant (p=0.7513). However, in this 
population, the percentage of PMs and UMs was lower than Portuguese Caucasian 
adult parturients (5% and 8%, respectively) (Figure 13).  
 
 
 Rosa Quinta, 2014  Page 49 
 
Figure 12 – Frequencies of metabolic profiles in a Portuguese Caucasian adult parturients. Abbreviations: 
PM, Poor Metabolizer; IM, Intermediate Metabolizer; EM, Extensive Metabolizer; UM, Ultrarapid 
Metabolizer. 
 
 
 
Figure 13 – Frequencies of metabolic profiles in a women Portuguese population (fertile age until 47 
years). Abbreviations: PM, Poor Metabolizer; IM, Intermediate Metabolizer; EM, Extensive Metabolizer; 
UM, Ultrarapid Metabolizer. 
 
 
Metabolic profiles according to the age of women, is presented in table 7. 
 
Table 7 – Sample characterization. 
 
PM IM EM UM 
Portuguese Caucasian 
women controls (n=53) 
3 21 27 2 
Portuguese Caucasian 
parturients (n=55) 
5 21 25 4 
Maternal age (yrs): 
Median 
Range 
 
33 
26-42 
 
32 
24-38 
 
32 
29-41 
 
31 
21-37 
Abbreviations: PM, Poor Metabolizer; IM, Intermediate Metabolizer; EM, Extensive Metabolizer; UM, UltraRapid 
Metabolizer; n, number of subjects; yrs, years. 
 
 
Women population vs parturients population 
The table 8 is representative of the comparison between Portuguese Caucasian 
adult women and a Portuguese Caucasian adult parturients. For alleles *6 and *17, it 
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comparison was not possible to perform because these allelic variants are absent in 
this population. The *41 allele variant was not determined in the normal population. 
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Table 8 – Comparison between Portuguese Caucasian Adult Parturients and a fertile population of Portuguese Caucasian Adult Women56. (Data from Albuquerque et al, 
2013) 
   
Populations Alleles 
Parturients 
Women 
n 95% CI 
Fertile 
Women§ 
n 95% CI 
n 
 
55 53 
Normal Alleles 
*1 0.509 56 0.417 - 0.600 0.368 39 0.282 - 0.463 
*2 0.064 7 0.031 - 0.125 0.340 36 0.257 - 0.434 
Defective Alleles 
*3 0.009 1 0.001 - 0.049 0.028 3 0.010 - 0.080 
*4 0.236 26 0.166 - 0.323 0.189 20 0.127 - 0.274 
*5 0.009 1 0.001 - 0.049 0.019 2 0.005 - 0.066 
*6 0.009 1 0.001 - 0.049 0 0 0 
Reduced activity 
alleles 
*10 0.009 1 0.001 - 0.049 0.038 4 0.015 - 0.093 
*17 0.009 1 0.001 - 0.049 0 0 0 
*41 0.100 11 0.056 – 0.170 - - - 
Multiplication 
Duplication 
*1xN or  
*2xN 
*1x2/*2 ou 
*1/*2x2 
*1/*1x2 
*2x3/*2 
*2/*2x2 
0.045 5 0.019 - 0.102 0.019 2 0.005 - 0.066 
§Women between 15 and 47 years old 
Abbreviations: CI, confidence interval; n, number of subjects; N, number of alleles. 
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Association genetic analysis 
Pain 
Samples of this study were classified according two groups of pain scoring: lower 
or equal to 3 and above 3 in all the measurements performed. Then it was analyzed 
the genotypic and allelic frequency according to different groups of pain. It was verified 
that in two genotype analysis, the results are only statistically significant for *2, *4 and 
*10. However, for allelic analysis, the results are not significant (Table 9). 
Parturients with haplotype CYP2D6*2 and that have pain above 3, 55% are 
heterozygous (CG) and in those that have pain less or equal to 3, 61% are homozygous 
to wt allele (CC). 
 Parturients with haplotype CYP2D6*4 and pain higher than 3, are mainly  
heterozygous (GA) 52%; and those that have pain less or equal than 3, 11% are 
homozygous to wt allele (AA). 
 Finally, in parturients with haplotype CYP2D6*10, that have pain greater than 3, 
48% are heterozygous (CT) and in those that have pain less or equal than 3, 75% are 
homozygous for wt allele (CC). All of the 3 CYP2D6 haplotypes presented are 
statistically significant for differences between groups (p=0.007). 
Due to the rare occurrence of the variants CYP2D6*3, *6 and *17, the statistical 
analysis was not performed for these cases. 
On the other hand, according to figure 14, its possible conclude that 56% of 
IMs+PMs present pain above 3 comparing with the other 36% of IMs+PMs parturients 
that present pain below 3. 
 
 
 
Figure 14 – Frequencies distribution of metabolic profiles according to development of pain.                 
A-Pain>3; B-Pain≤3. 
A B 
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Pruritus 
Samples of this study were classified according to the presence or absence of 
pruritus for any time of measurement after morphine administration. Then the 
possibility of analyzing the genotype and allele frequencies according to the two 
different groups. It was verified that results concerning *2, *4 and *10 alleles are 
statistically not significant for genotype analyzes; however for allele analyzes, the 
results are statistical significant for *2 and *10; p-value is borderline for *4 (Table 9). 
From the parturients with haplotype CYP2D6*2 and with pruritus, 39% are 
homozygous for wt allele (CC) and in those without pruritus, 57% are homozygous for 
wt allele (CC). 
 Parturients with haplotype CYP2D6*4 and with pruritus, are mainly homozygous 
(GG) 44%; and 67% without pruritus, are homozygous (GG). 
 Finally, in parturients with haplotype CYP2D6*10, having pruritus, 45% are 
homozygous for wt allele (CC) and in those without pruritus, 70% are homozygous 
(CC). 
Due to the scarce number of the variants for CYP2D6*3, *6 and *17, the 
statistical analysis was not performed in these cases. 
According to figure 15, there are more EMs parturients with pruritus than 
without pruritus (46% and 50%, respectively).  
Concerning nausea and vomiting, it was not possible to perform statistical 
analysis for none of the variants, because almost all results were nulls.  
 
 
Figure 15 – Frequencies distribution of metabolic profiles according to development of ADR pruritus.   
A-Presence of pruritus; B-Absence of pruritus. 
 
  
A B 
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Table 9 – Genotypic and allelic frequency. 
Genotype 
Combined 
Allele 
Predicted 
Activity 
N Pain ≤ 3 Pain >3 
Presence 
of 
Pruritus 
Absence 
of 
Pruritus 
 
n Allele Pain ≤ 3 Pain >3 
Presence 
of 
Pruritus 
Absence 
of 
Pruritus 
c.1457C>G  
(rs1135840) 
       
 
 
    
GG 
*2 Normal 55 
5 (0.18) 1 (0.03) 5 (0.28) 1 (0.02)  G 
 
C 
16 (0.29) 
 
40 (0.71) 
17 (0.31) 
 
37 (0.69) 
16 (0.44) 
 
20 (0.56) 
17 (0.23) 
 
57 (0.77) 
GC 6 (0.21) 15 (0.56) 6 (0.33) 15 (0.41) 110 
CC 17 (0.61) 11 (0.41) 7 (0.39) 21 (0.57)  
p p *0.020 *0.019  p 0.839 *0.027 
c.775delA 
(rs35742686)   
     
  
 
 
 
AA 
*3 Null 55 
27 (0.96) 27 (1.00) 17 (0.94) 37 (1.00)  A 
 
Del 
55 (0.98) 
 
1 (0.02) 
54 (1.00) 
 
0 (0.00) 
35 (0.97) 
 
1 (0.03) 
74 (1.00) 
 
0 (0.00) 
ADel 1 (0.04) 0 (0.00) 1 (0.06) 0 (0.00) 110 
DelDel 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)  
p  p – –  p 1.000 0.327 
c.506-1G>A 
(rs3892097)   
     
  
 
 
 
GG 
*4 Null 55 
21 (0.75) 12 (0.44) 8 (0.44) 25 (0.67)  G 
 
A 
46 (0.82) 
 
10 (0.18) 
38 (0.70) 
 
16 (0.30) 
23 (0.64) 
 
13 (0.36) 
61 (0.82) 
 
13 (0.18) 
GA 4 (0.14) 14 (0.52) 7 (0.39) 11 (0.30) 110 
AA 3 (0.11) 1 (0.04) 3 (0.17) 1 (0.03)  
p  p *0.011 0.098  p 0.180 0.054 
c.454delT 
(rs5030655)   
     
  
 
 
 
TT 
*6 Null 55 
27 (0.96) 27 (1.00) 17 (0.94) 37 (1.00)  T 
 
Del 
55 (0.98) 
 
1 (0.02) 
54 (1.00) 
 
0 (0.0) 
35 (0.97) 
 
1 (0.03) 
 
74 (1.00) 
 
0 (0.00) 
TDel 1 (0.04) 0 (0.00) 1 (0.06) 0 (0.00) 110 
DelDel 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)  
p  p – –  p 1.000 0.327 
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Genotype 
Combined 
Allele 
Predicted 
Activity 
N Pain ≤ 3 Pain >3 
Presence 
of 
Pruritus 
Absence 
of 
Pruritus 
 
n Allele Pain ≤ 3 Pain >3 
Presence 
of 
Pruritus 
Absence 
of 
Pruritus 
c.100C>T 
(rs1065852)   
     
  
 
 
 
CC 
*10 Decrease 55 
21 (0.75) 13 (0.48) 8 (0.45) 26 (0.70)  C 
 
T 
45 (0.80) 
 
11 (0.20) 
39 (0.72) 
 
15 (0.28) 
2(0.61) 
 
14 (0.39) 
62 (0.84) 
 
12 (0.16) 
CT 3 (0.11) 13 (0.48) 6 (0.33) 10 (0.27) 110 
TT 4 (0.14) 1 (0.04) 4 (0.22) 1 (0.03)  
p  p **0.007 *0.034  p 0.363 *0.016 
c.320 C>T 
(rs28371706)   
     
  
 
 
 
CC 
*17 Decrease 55 
28 (1.00) 26 (0.96) 18 (1.00) 65 (0.97)  C 
 
T 
50 (1.00) 
 
0 (0.00) 
52 (0.96) 
 
2 (0.04) 
36 (1.00) 
 
0 (0.00) 
72 (0.97) 
 
2 (0.03) 
CT 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 110 
TT 0 (0.00) 1 (0.04) 0 (0.00) 1 (0.03)  
p  p – –  p 0.239 1.000 
c.985+39 
G>A 
(rs28371725) 
      
  
 
 
 
GG 
*41 Decrease 55 
23 (0.82) 23 (0.85) 18 (1.00) 28 (0.76)  G 
 
A 
46 (0.82) 
 
10 (0.18) 
49 (0.91) 
 
5 (0.09) 
36 (1.00) 
 
0 (0.00) 
59 (0.80) 
 
15 (0.20) 
GA 0 (0.00) 3 (0.11) 0 (0.00) 3 (0.08) 110 
AA 5 (0.18) 1 (0.04) 0 (0.00) 6 (0.16)  
p  p 0.059 0.073  p 0.268 *0.002 
 
Legend: n = number of parturients; *p<0.05; **p<0.01. 
Note: To *3, *6 and *17 it was not possible calculate the p-value because one row is filled with zeros is in the contingency table.  In this situation, chi-square analysis is 
impossible.  At least one of these values must be positive. 
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4. Comment 
 
In this study, we analyze the CYP2D6 gene, in a sample of 55 Portuguese 
Caucasian adult parturients, to whom morphine was given morphine for analgesia after 
cesarean section. 
The definition of a specific haplotype for this gene, through the seven variations 
studied g.997C>G (rs1135840, c.1457C>G), g.2549DelA (rs35742686, c.775delA), 
g.1846G>A (rs3892097, c.506-1G>A), g.1707DelT (rs5030655, c.454DelT), g.100C>T 
(rs1065852, c.100C>T) and g.1023C>T (rs28371706, c.320 C>T) g.2988G>A 
(rs28371725, c.985+39G>A) and the phenotype approach is very closely compared to 
the profile of an individual’s metabolism.  
According to the results, only 3 alleles were statistical significant in this study: *2 
(rs1135840, c.1457C>G), *4 (rs3892097, c.506-1G>A) and *10 (rs1065852, 
c.100C>T). 
From the present results, it is possible to observe that the most frequent 
CYP2D6 combined allele was the normal and functional allele, wt or *1, followed by 
allele *4. We have also confirmed the presence of alleles *10, *17 and *41 in a 
Portuguese population, which was expected due to the knowledge of existing Asian 
and African ancestors, respectively56,94.  The PM frequency observed in parturients (5%) 
is in agreement with previous studies that estimate 5-10% of PM in the European 
Caucasian population56,94. Accordingly, it is estimated that, taking into account the 
number of women estimated by CENSUS 2011 (5,515,578)95 there are approximately 
275,778 PMs in Portugal. 
The UM frequency observed in parturients is 0.073 (8%) and is slightly higher 
than the previous studies which is between 3-5%49. According to the Portuguese 
populations CENSUS, we estimate that there are approximately 441,246 UM in 
Portugal. 
Comparing data of this population of parturients with the women Caucasian in 
general population, it is possible to conclude that the IMs and EMs are very similar in 
both groups. However, there are more PMs and UMs in the parturients (9% and 7%, 
respectively) comparing with women Caucasian, population (5% and 8%, respectively) 
but differences are not significant (Figure 12).  
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After analysis of this sampling, it was analyzed the alleles *2, *4 and *10 for 
genotype, allele and their metabolic profile, according to pain scores and presence or 
absence of pruritus, were analyzed. 
Concerning the results of genotypes and pain scoring, it was verified that all 3 
alleles present statistical differences for pain scoring. The pain score is higher in 
parturients that are heterozygous for *4 and *10 frequency, probably due to an 
enzyme reduction function.  
The comparison between predicted metabolic phenotype and pain does not 
present any statistical significant results. 
To explain the continuation of pain after morphine administration, there are 
some theories discuted in literature. 
According to Timothy S. Tracy et al.96, pregnancy is a dynamic state during which 
a number of physiologic and biochemical changes occur. Furthermore, the extent of 
these changes may be affected by the stage of pregnancy. CYP2D6 metabolizes several 
drugs that are used clinically in the care of parturients and has been reported that the 
metabolism of these drugs increase significantly during pregnancy, compared with the 
post-partum period. The increase of CYP2D6 activity throughout the course of 
pregnancy is considering the generally held notion that CYP2D6 is not inducible, at 
least by xenobiotics. The most obvious potential inducing substance would be the 
elevated endogenous hormones (e.g., estrogen and progesterone) that occur during 
pregnancy. However, there are not data to suggest that these hormones can induce 
CYP2D6 activity, which suggests that other endogenous compounds may be 
responsible for the observed induction of CYP2D6. 
CYP2D6 is highly polymorphic and plays an important role in the hepatic 
metabolism of therapeutic agents including drugs affecting the CNS (Central Nervous 
System) and other xenobiotics. CYP2D6 is also expressed in the human brain. 
Furthermore, recent in vitro and in vivo animal studies support CYP2D6 involvement in 
the biotransformation of endogenous substances such as 5-methoxyindolethylamine O-
demethylase potentially contributing to regeneration of serotonin from 5-
methoxytryptamine (5MT). As dopaminergic neurotransmission is regulated by 
serotonin, CYP2D6 may exert a nuanced (serotonergic) influence on dopaminergic 
tone in the pituitary. The 5MT exists in the brain including in the serotonergic raphe 
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nucleus and the pineal gland. Dopamine, another neuroactive amine, is thought to be 
formed in part by hydroxylation of tyramine via CYP2D6 intervention. The total 
amount of CYP2D6 in the brain is much lower than in the liver, and tyramine derived 
from food does not cross the blood–brain barrier. The concentration of dopamine in 
the brain is high, since the classic biosynthetic route to dopamine from tyrosine is very 
active. However, tyramine can be formed in the brain, especially in the basal ganglia, via 
the aromatic hydroxylation of phenylethylamine or via tyrosine decarboxylation to give 
tyramine, which is a CYP2D6 substrate for dopamine synthesis60,61,97. 
Accordingly to Lledó et al60, CYP2D6 PMs, who have null enzyme capacity, 
appear to present a reduction in regeneration of serotonin, which in turn may cause a 
slightly elevated dopamine tone due to the inverse correlation between the serotonin 
and dopamine systems. Anatomical and pharmacological evidence suggests that the 
dorsal raphe serotonin system and the ventral tegmental and substancia nigra 
dopamine system may act as mutual opponents for some psychological functions. 
Pharmacological studies show that dopamine is involved in activating behaviors 
that serotonin inhibits and vice-versa. As previously described in literature, serotonin 
is implicated in the maintenance of psychological balance, and malfunction in its 
production is for example responsible for depression, aggression, impulsivity, 
obsessionality, analgesia, hallucinations, attention and mood63.  
Dopamine neurotransmission has an important influence on outcome prediction, 
attention, response inhibition, and motivation, as well as affective symptoms associated 
with anxiety and depression24. 
It is known that the action of morphine in the CNS promotes the activity of the 
dopaminergic neurons by the increase of release of dopamine to the synaptic gap to 
control pain. 
So it possible to conclude that the haplotypes resulting in absence on reduction 
of enzyme function are positively correlated with higher pain scores (Figure 14). This is 
possibly related to a decrease of dopamine synthesis by tyramine pathway. 
Consequently, the activation of signal transduction pathway that controls neuronal pain 
and analgesic effect may be reduced, leading to an increase of pain after cesarean. 
However, this is only verified if we consider the PM and IM together because the 
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number of samples is low, so it is necessary to take into account the preliminary 
nature of this work. 
Thus, subjects with partial or null function of CYP2D6 enzyme could not 
metabolize tyramine effectively, leading to decreased of dopamine content. 
Consequently, the activation of signal transduction pathway that controls neuronal pain 
and analgesic effect may be reduced, leading to increased of pain after cesarean section. 
 
The results by genotype show that there are not statistical differences for 
presence or absence of pruritus for *2, *4 and *10 allele. It was demonstrated that 
there are an increased number of homozygous of wt allele comparing to heterozygous. 
Analysis by allele, show that there are statistical significant results for alleles *2 
(rs1135840, c.1457C>G) and to *10 (rs1065852, c.100C>T). For *4 (rs3892097, 
c.506-1G>A), there is not significance (p=0.0985). This results show that parturients 
with pruritus have higher prevalence of variant allele, meaning that allelic variation 
influence the emerging of ADRs. 
Comparison between PM phenotype vs others phenotypes and pruritus, shown 
that there are significant differences (p = 0.0350). This demonstrates that a higher 
number of PM parturients have pruritus comparing with PM parturients. In figure 15 it 
is possible to observe that 44% of parturients from the set of PM and IM have pruritus 
comparing with 46% of PM and IM set parturients with absence of pruritus.  
This present study is relevant because there is no data in literature that relates 
the presence of pruritus with metabolic profiles associated to CYP2D6 gene. However 
the scientific knowledge about this side effect is limited. Pruritus is an important 
symptom of many skin, systemic and autoimmune diseases, a troubling side effect of a 
number of medications, like morphine41. By definition, it is a sensation that provokes 
the uncontrollable need to scratch and can be aroused by a variety of mechanical, 
electrical and chemical stimuli. The exact mechanism of neuroaxial opioid-induced 
pruritus remains unclear. Postulated mechanisms include the presence of an “itch 
center” in the central nervous system, medullary dorsal horn activation, and 
antagonism of inhibitory transmitters. Modulation of the serotoninergic pathway and 
involvement of prostaglandins may also be important in the etiology of neuroaxial 
opioid-induced pruritus. Prostaglandins (PGE1 and PGE2) enhance C fiber transmission 
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to the CNS and they are also known to release histamine and potentiate pruritus 
induced by histamine98,99. 
Histamine, and compounds which release peripheral histamine from mast cells, 
are the primary experimental itch mediators in humans41. 
 The reported incidence of pruritus varies between 30% and 100%. Parturients of 
the present work appear to be more susceptible, with an incidence between 60% and 
100%. This increased incidence may be due to an interaction of estrogen with opioid 
receptor. The treatment of intrathecal and epidural opioid-induced pruritus remains a 
challenge. However, many pharmacological therapies, including antihistamines, 5-HT3-
receptor antagonists, opiate-antagonists (ex. intravenous naloxone), propofol, 
nonsteroid antiinflammatory drugs, and droperidol, have been studied. In the present 
study, when women had severe pruritus, it was administrated naloxone that can 
reduced or reverse morphine-induced pruritus in 80%, according to Jeon et al40.  
Morphine produces part of its analgesic effect through the release of serotonin. 
There are dense concentrations of serotonin receptors in the dorsal part of spinal 
cord and the nucleus of the spinal tract of the trigeminal nerve in the medulla opioid 
density is also high. These observations suggest that the 5-HT3 receptor may be 
implicated in the development of the pruritus associated with administration of 
neuroaxial opioids41,67. 
However, according to Green et al41, serotonin is a powerful pruritic agent in 
mice, but it appears that there are important differences between rodents and humans 
in the relative involvement of histamine and serotonin in the mediation of itch. 
Comparing pruritus and pain by phenotype, it was concluded that there are not 
statistically significant results, suggesting that there is not a correlation between both 
parameters. 
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5. Conclusions  
 
This study allowed the setting the CYP2D6 pharmacogenetic analysis in a 
population of Portuguese Caucasian adult parturients and it relation with pain scores 
and the presence or absence of pruritus. 
According to the results, it is possible to conclude that the haplotypes that result 
in absence and reduction of enzyme function are positively correlated with higher pain 
scores. This is possibly related to a decrease of dopamine synthesis by tyramine 
pathway. Consequently, the activation of signal transduction pathway that controls 
neuronal pain and analgesic effect may be reduced, leading to an increase of pain after 
cesarean. However, the exact mechanism of neuroaxial opioid-induced pruritus 
remains unclear. 
It was also analyzed the homogeneity of frequencies in the Portuguese Caucasian 
women, with the same range of ages. Interindividual differences in drug disposition are 
important causes for ADRs and lack of drug response. However, in future, it is 
necessary to increase the number of samples in order to obtain a better confidence 
level of analysis.  
There is no doubt that genetic variants affect drug responses to an extent that 
can have relevant implications beyond just the efficacy of a prescribed drug. For the 
clinician, and in particular for the anesthesiologist providing anesthesia and post-
operative pain management, there are to date no guidelines or recommendations that 
suggest any pharmacogenetic testing prior to administering any anesthesia-related drug.  
Pharmacogenetics is a rapidly developing field. Faster and cheaper methods of 
genotyping will be available in the near future and this will enable cost-effective 
preoperative testing of parturients88 in order to improve drug safety, dosage 
recommendations, decreased of pain and pharmacovigilance programs which would 
benefit millions of parturients worldwide.  
This work contributes to a better understanding of how the CYP2D6 allelic 
variants may affect pain (and pruritus) and bring light to the treatment of labor 
analgesia. However, further studies with a higher number of parturients will be 
necessary to confirm the present results. 
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6. Future directions  
 
The scientific developments in pharmacogenomics, and the potential clinical and 
economic impact of this area, will eventually make genotyping a clinical practice 
routine. Before widespread clinical use becomes a reality, a host of 
pharmacogenomics-based clinical trials will be carried out13. 
The future impact of PGx is likely to be considerable both in the selection of the 
right drug at the proper ‘individual’ dose and in the prevention of adverse effects. By 
translating the increasing knowledge of human genetic diversity into better drug 
treatment, improved health through personalized therapy remains a realistic future 
scenario in many fields of medicine100. 
The goal of individualized medicine is to prescribe an appropriate medication to 
the right target of the disease, at the right dose, to achieve maximal therapeutic benefit 
with minimal, tolerable ADRs. However, good clinical data to support the use of 
genetic testing for drug treatment for most diseases are still not available10. 
On the other hand, pharmacogenomic polymorphisms are definitely important in 
interindividual variability in the analgesic effects and occurrence of ADRs of commonly 
used medications, but genetic factors will provide only a partial answer to this 
interindividual variability. Other factors, including biological variations (ethnicity, age 
and gender), environmental factors (smoking status), co-morbidity and co-medications 
(potential for drug-drug interactions) must be considered, because is the synergestic 
effect that also influence the pharmacokinetics and pharmacodynamics of medications 
used for pain management32. 
In the near future, pharmacogenomic approaches in pain management could lead 
to individualized therapy to best select the appropriate analgesic from the onset to 
provide sustained efficacy with the lowest side effect profile32. 
 
 
Rosa Quinta, 2014  Page 64 
 Rosa Quinta, 2014  Page 65 
7. Acknowledgements 
 
This study was financed in Spain by the RIBEF Iberoamerican Network of 
Pharmacogenomics, and it was partially supported by Portuguese Foundation for 
Science and Technology (FCT), with the Strategic Project PEst-C/SAU/LA0001/2011. 
 
The authors of this study have no other relevant affiliations or financial 
involvement with any organization or entity with a financial interest in or financial 
conflict with the subject matter or materials discussed in the manuscript apart from 
those disclosed. 
 
 
 
 
 
 Rosa Quinta, 2014  Page 66 
 
 Rosa Quinta, 2014  Page 67  
8. References 
 
1. Garrod, A. E. (1902). The incidence of alkaptonuria: a study in chemical 
individuality. The Lancet, ii, 1616–1620. 
2. Vesell, E. S. (1978). Twin studies in pharmacogenetics. Human Genetics. 
Supplement, 30(1), 19–30. 
3. Roden, D. M., Wike, R. A., Kroemer, H. K., & Stein, M. (2011). 
Pharmacogenomics: The genetics of variable drug responses. National Institute of Health, 
123(15), 1661–1670. 
4. Vogel F. (1959). Moderne problem der humangenetik. Ergeb Inn Med U 
Kinderheilk. 12:52–125. 
5. Kataria, R., Katkkar, A., & Gagoria, J. (2013). Pharmacogenetics: genetically 
determined variations in drug response, 3(2), 288–293. 
6. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., Leeder, S. J.. (2006) 
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-
prescribed mother. Case Study. The Lancet, 368, 704. 
7. Voora, D., & Ginsburg, G. S. (2012). Clinical application of cardiovascular 
pharmacogenetics. Journal of the American College of Cardiology, 60(1), 9–20.  
8. Rodeiro, I., Figueredo, D. R., Mesa, M. G., Dorado, P., & Llerena, A. (2012). 
Pharmacogenetics in Latin American populations: regulatory aspects, application to 
herbal medicine, cardiovascular and psychiatric disorders. Drug Metab. Drug Interact, 27, 
57–60. 
9. Karczewski, K. J., Daneshjou, R., & Altman, R. B. (2012). Chapter 7: 
Pharmacogenomics. PLOS Computational Biology, 8. 
10. Ma, Q., & Lu, A. Y. H. (2011). Pharmacogenetics, Pharmacogenomics and 
Individualized Medicine. Pharmacological Reviews, 63(2), 437–459.  
11. Center for Genetics Education. (2007). Pharmacogenetics / Pharmacogenomics - 
Fact sheet 25. NSW Health, 1–3. 
12. Shastry, B. S. (2006). Pharmacogenetics and the concept of individualized 
medicine. The Pharmacogenomics Journal, 6(1), 16–21. 
 Page 68   Rosa Quinta, 2014 
13. Issa, A. M. (2002). Ethical perspectives on pharmacogenomic profiling in the drug 
development process. Nature Reviews. Drug Discovery, 1(4), 300–8. 
14. Piatkov, I., Jones, T., & Mclean, M. (2013). Drug Interactions , Pharmacogenomics 
and Cardiovascular Complication. INTECH Open Science. 
15. Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. 
(2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. The New 
England Journal of Medicine, 351(27), 2827–31. 
16. Schwab, M., & Schaeffeler, E. (2012). Pharmacogenomics: a key component of 
personalized therapy. Genome Medicine, 4(11), 93. 
17. Weinshilboum, R., & Wang, L. (2009). Pharmacogenomics: bench to bedside. 
Mayo Medical School. 
18. European Medicines Agency. Science Medicines Health. 2014. [accessed at 
07/07/2014]. Available on: http://www.ema.europa.eu/ema/. 
19. Ventola, C. L. (2011). Pharmacogenomics in clinical practice: reality and 
expectations. P & T: A Peer-Reviewed Journal for Formulary Management, 36, 412–50. 
20. Ingelman-Sundberg M.. (2005) Genetic polymorphisms of cytochrome P450 2D6 
(CYP2D6): clinical consequences, evolutionary aspects and functional diversity. 
Pharmacogenomics J. 5(1):6–13 
21. Cabrita, J., & Soares, M. A. (2012). Reações Adversas a Medicamentos: Análise da 
base de dados do Sistema Nacional de Farmacovigilância (SVIG). Infarmed - Autoridade 
Nacional Do Medicamento E Produtos de Saúde, 2009–2011. 
22. VanderVaart, S., Berger, H., Sistonen, J., Madadi, P., & Matok, I. (2011). CYP2D6 
Polymorphism and Codeine Analgesia in Postpartum Pain Management: a pilot atudy. 
The Drug Monit, 33, 425–432. 
23. Ghosh, S. (2012). Introduction to Pain, Religion and Analgesia. INTECH, 1–10. 
24. Jarcho J.M., Mayer E.A., Jiang Z.K., Feier N.A., London E.D.. (2012) Pain, affective 
symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain. 
153(4):744–54.  
 Rosa Quinta, 2014  Page 69  
25. Tavares I., Lima D. (2007). From neuroanatomy to gene therapy: searching for 
new ways to manipulate the supraspinal endogenous pain modulatory system. Journal 
Anatomy, 211:261-268. 
26. P.R., K., A.F.P.F., W., & T, S. (2008). Pathophysiology of pain. Veterinary Science, 
13(1), 1–12. 
27. International Association for the Study of Pain: Pain Defenition. 2014. [accessed 
at 07/07/2014]. Available on: http://www.iasp-pain.org/. 
28. European Pain Federation EFIC®. About Pain. 2014. [accessed at 07/07/2014]. 
Available on: http://www.efic.org/index.asp?sub=OEIX4QVHa073B4. 
29. Woolf, C. J., & Max, M. B. (2001). Mechanism-based pain diagnosis. 
Anesthesiology, 95(1), 241–9. 
30. Buskila, D., Neumann, L., & Press, J. (2005). Genetic factors in neuromuscular 
pain. CNS Spectrums, 10(4), 281–4. 
31. Smith M.T., Muralidharan A.. (2012) Pharmacogenetics of pain and analgesia. Clin. 
Genet. 82(4):321–30. 
32. Jannetto P.J., Bratanow N.C.. (2010) Pharmacogenomic considerations in the 
opioid management of pain. Genome Med. 2(9):66. 
33. Vuilleumier P.H., Stamer U.M., Landau R.. (2012) Pharmacogenomic 
considerations in opioid analgesia. Pharmgenomics. Pers. Med. 5:73–87. 
34. Maurer H.H., Sauer C., Theobald D.S.. (2006) Toxicokinetics of drugs of abuse: 
current knowledge of the isoenzymes involved in the human metabolism of 
tetrahydrocannabinol, cocaine, heroin, morphine and codeine. Drug Monit. 28(3):447–
453. 
35. Zhu, W., Mantione, K. J., Shen, L., Cadet, P., Esch, T., Goumon, Y., Stefano, G. B. 
(2005). Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine 
levels in vitro and in vivo: cyp2d6 and tyrosine hydroxylase modulation demonstrates a 
dopamine coupling. Medical Science Monitor: International Medical Journal of 
Experimental and Clinical Research, 11(11), BR397–404. 
36. Madadi, P., Avard, D., & Koren, G. (2012). Pharmacogenetics of opioids for the 
treatment of acute maternal pain during pregnancy and lactation. Current Drug 
Metabolism, 13(6), 721–7. 
 Page 70   Rosa Quinta, 2014 
37. Chaney, M. A. (1995). Review Article Side effects of intrathecal and epidural 
opioids. Can J Anaesth, 42, 891–903. 
38. Sanansilp, V., Areewatana, S., & Tonsukchai, N. (1998). Droperidol and the Side 
Effects of Epidural Cesarean Section. Anesth Analg, 86, 532–537. 
39. Kolm, A., Alberto, A., Ferraz, F., Sueli, N., Módolo, et al. (2006). Prevention of 
itching after spinal sufentanil: effects of droperidol, nalbuphine, ondansetron and the 
association of them. Rev Bras Anestesiol, 56, 28–33. 
40. Jeon Y., Hwang J., Kang J., Han S., Rhee K., Oh Y.. (2005) Effects of epidural 
naloxone on pruritus induced by epidural morphine: a randomized controlled trial. Int. 
J. Obstet. Anesth. 14(1):22–5. 
41. Green A.D., Young K.K., Lehto S.G., Smith S.B., Mogil J.S.. (2006) Influence of 
genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain. 
124(1-2):50–8. 
42. Searle, R., & Hopkins, P. M. (2009). Pharmacogenomic variability and anaesthesia. 
British Journal of Anaesthesia, 103(1), 14–25. 
43. Liska, D. J. (1998). The detoxification enzyme systems. Alternative Medicine 
Review: A Journal of Clinical Therapeutic, 3(3), 187–98. 
44. Williams, R.T.. (1947) Detoxication Mechanisms: The Metabolism and 
Detoxication of Drugs, Toxic Substances and Other Organic Compounds.  2nd ed. 
New York:  J.Wiley & Sons. 
45. Pinto, N., & Dolan, M. E. (2011). Clinically relevant genetic variations in drug 
metabolizing enzymes. Current Drug Metabolism, 12(5), 487–97.  
46. Prasad, S., & Mitra, S. (2004). Structure and Mechanism of function of 
Cytochrome P450. Proc. Indian Natn Sci Acad, 70, 283–291. 
47. Söderbäck, E., Zackrisson, A.-L., Lindblom, B., & Alderborn, A. (2005). 
Determination of CYP2D6 gene copy number by pyrosequencing. Clinical Chemistry, 
51(3), 522–31. 
48. Wunsch, M. J., Stanard, V., & Schnoll, S. H. (2003). Treatment of Pain in 
Pregnancy. The Clinical Journal of Pain, 19, 148–155. 
 Rosa Quinta, 2014  Page 71  
49. Cascorbi, I. (2003). Pharmacogenetics of cytochrome p4502D6: genetic 
background and clinical implication. European Journal of Clinical Investigation, 33 Suppl 2, 
17–22.  
50. Dorado P., Cáceres M., Pozo-Guisado E., Wong M.-L., Licinio J., Llerena A.. 
(2005) Development of a PCR-based strategy for CYP2D6 genotyping including gene 
multiplication of worldwide potential use. Pharmacogenomics. 39:571–574.  
51. Von Ahsen, N., Tzvetkov, M., Karunajeewa, H. a, Gomorrai, S., Ura, A., 
Brockmöller, J., et al. (2010). CYP2D6 and CYP2C19 in Papua New Guinea: High 
frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. 
International Journal of Molecular Epidemiology and Genetics, 1(4), 310–9. 
52. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C.. (2007) 
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, 
pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3):496–526. 
53. Niwa, T., Hiroi, T., Tsuzuki, D., Yamamoto, S., Narimatsu, S., Fukuda, T., Funae, 
Y. (2004). Effect of genetic polymorphism on the metabolism of endogenous 
neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain 
Research. Molecular Brain Research, 129(1-2), 117–23.  
54. Menoyo, A., del Rio, E., & Baiget, M. (2006). Characterization of variant alleles of 
cytochrome CYP2D6 in a Spanish population. Cell Biochemistry and Function, 24(5), 381–
5. 
55. Zhou S.. (2009) Polymorphism of human cytochrome P450 2D6 and its clinical 
significance. Clin. Pharmacokinet. 48(11):689–723. 
56. Albuquerque J., Ribeiro C., Naranjo M.E.G., Llerena A., Grazina M.. (2013) 
Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese 
population: pharmacogenetic implications. Per. Med. 10:709–718. 
57. Gardiner, S. J., & Begg, E. J. (2006). Pharmacogenetics, Drug-Metabolizing 
Enzymes, and Clinical Practice. Pharmacological Reviews, 58(3), 521–590.  
58. Llerena, A., Dorado, P., Peñas-Lledó, E. M., Cáceres, M. C., & De la Rubia, A. 
(2007). Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. 
The Pharmacogenomics Journal, 7(6), 408–10. 
 Page 72   Rosa Quinta, 2014 
59. Hiroi, T., Imaoka, S., & Funae, Y. (1998). Dopamine formation from tyramine by 
CYP2D6. Biochemical and Biophysical Research Communications, 249(3), 838–43. 
60. Peñas-lledó E.M., Dorado P., Pacheco R.. (2009) Relation between CYP2D6 
genotype, personality, neurogognition and overall psychopathology in healthy 
volunteers. Pharmacogenomics. 10(7):1111–1120. 
61. Ozdemir V., Bertilsson L., Miura J., et al. (2007) CYP2D6 genotype in relation to 
perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: 
CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet. Genomics. 17(5):339–
47.  
62. Schyman P., Usharani D., Wang Y., Shaik S.. (2010) Brain chemistry: how does 
P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield 
serotonin? J. Phys. Chem. B. 114(20):7078–89. 
63. Daw N.D., Kakade S., Dayan P.. (2002) Opponent interactions between 
serotonin and dopamine. Neural Networks. 15(4-6):603–616. 
64. The Human Cytochrome P450 Allele Nomenclature Database. 
http://www.cypalleles.ki.se/cyp2d6.htm 
65. Kimura, S., Umeno, M., Skodaj, R. C., Meyert, U. A., & Gonzalez, F. J. (1989). 
Sequence and Identification of the Polymorphic CYP2D6 Gene , a Related Gene , and a 
Pseudogene. Am. J. Hum. Genet., 45, 889–904. 
66. Kagimoto, M., Heim, M., Kagimoto, K., & Zeugin, T. (1990). Multiple Mutations of 
the Human Cytochrome P450 2D6 ( CYP2D6 ) in Poor Metabolizers of Debrisoquine. 
The Journal of Biological Chemistry, 265. 
67. Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M., & 
Hiratsuka, M. (2008). Functional Characterization of 17 CYP2D6 Allelic Variants 
(CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53– 55, and 57). Drug Metabolism and 
Disposition, 36(12), 2460–2467. 
68. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S.. 
(2008) The CYP2D6 activity score: translating genotype information into a qualitative 
measure of phenotype. Nature. 83(2):234–242. 
69. Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saussele, T., Raimundo, S., 
Schwab, M. (2006). Impaired expression of CYP2D6 in intermediate metabolizers 
 Rosa Quinta, 2014  Page 73  
carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation 
of splicing events. Pharmacogenetics and Genomics, 16, 5–6. 
70. Brousseau D.C., McCarver D.G., Drendel A.L., Divakaran K., Panepinto J.A.. 
(2007) The effect of CYP2D6 polymorphism on the response to pain treatment for 
pediatric sickle cell pain crisis. J Pediatr. 150(6):623–626. 
71. Schaeffeler E., Schwab M., Eichelbaum M., Zanger U.M.. (2003) CYP2D6 
genotyping strategy based on gene copy number determination by TaqMan Real-Time 
PCR. Hum. Mutat. 485(22):476–485. 
72. Llerena A., Dorado P., Ramírez R., et al.. (2010) CYP2D6 genotype and 
debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. 
12(2):176–83. 
73. Scordo, M. G., Caputi, A. P., D’Arrigo, C., Fava, G., & Spina, E. (2004). Allele and 
genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. 
Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 
50(2), 195–200. 
74. Dorado, P., Peñas-Lledó, E. M., & Llerena, A. (2007). CYP2D6 polymorphism: 
implications for antipsychotic drug response, schizophrenia and personality traits. 
Pharmacogenomics, 8(11), 1597–1608. 
75. Prado, C. M. do (2009). Desenvolvimento de metodologia para a determinação 
dos genótipos principais dos genes CYP2D6, CYP2C19 e CYP2C9: aplicação na 
Farmacogenética. Master Thesis. 
76. Zanger U.M., Raimundo S., Eichelbaum M.. (2004) Cytochrome P450 2D6: 
overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s 
Arch Pharmacol. 369:23–37. 
77. Ballantyne J.C., Cousins M.J.. (2009) Giamberardino M.A., et al.. What Does Pain 
Hurt? Int. Assoc. Study Pain. XVII(3). 
78. Carr D.B., Eisenberg E., Fricton J.R., et al.. (2005) Genetics, Pain and Analgesia. 
Int. Assoc. Study Pain. XIII(3):1–4. 
79. Landau R., Kraft J.C., Flint L.Y., et al.. (2010) An experimental paradigm for the 
prediction of Post-Operative Pain (PPOP). J. Vis. Exp. (35):3–6. 
80. Broussard C.S., Rasmussen S.A., Reefhuis J., et al.. (2011) Maternal treatment 
with opioid analgesics and risk for birth defects. Am. J. Obstet. Gynecol. 204:314.e1–11. 
 Page 74   Rosa Quinta, 2014 
81. Landau R., Kern C., Columb M.O., Smiley R.M., Blouin J.-L.. (2008) Genetic 
variability of the µ-opioid receptor influences intrathecal fentanyl analgesia 
requirements in laboring women. Pain. 139(1):5–14. 
82. Kopecky E.A., Ryan M.L., Barrett J.F., et al.. (2000) Fetal response to maternally 
administered morphine. Am. J. Obstet. Gynecol. 183(2):424–30. 
83. Wu C.L., Raja S.N.. (2011) Treatment of acute postoperative pain. Lancet. 
377(9784):2215–25.  
84. Kaye A.D., Hoover J.M., Kaye A.J., et al.. (2008) Morphine, opioids, and the feline 
pulmonary vascular bed. Acta Anaesthesiol. Scand. 52(7):931–7. 
85. Fox SI.. (2011) Human Physiology. 12nd ed. (McGraw-Hill). Los Angeles; 214-217. 
86. Martis S., Mei H., Vijzelaar R., Edelmann L., Desnick R.J., Scott S.A.. (2012) Multi-
ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and 
mechanism of copy number variation formation. Pharmacogenomics J. 1–9. 
87. Raposo A.B.. (2011) Variação genética do gene CYP2D6 na analgesia do parto: 
abordagem farmacogenómica. Master Thesis. 1–92 
88. Stamer U.M., Lehnen K., Ho F., et al.. (2003) Impact of CYP2D6 genotype on 
postoperative tramadol analgesia. Pain. 105:231–238.  
89. Lötsch J., Rohrbacher M., Schmidt H., Doehring A., Brockmöller J.. (2009) Can 
extremely low or high morphine formation from codeine be predicted prior to 
therapy initiation? Pain. 144(1-2):119–124. 
90. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A.. (1991) Deletion of 
the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in 
poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 
48(5):943–50.  
91. Motulsky H.J.. (1999) Analyzing Data with GraphPad Prism. GraphPad Software 
Inc., San Diego CA. www.graphpad.com. 
92. Raosoft Sample size calculator. http://www.raosoft.com/samplesize.html. 
93. VassarStats: Website for Statistical Computation. 
http://www.vassarstats.net/index.html. 
94. Thorn C.F., Klein T.E., Altman R.B.. (2009) Codeine and morphine pathway. 
Pharmacogenet. Genomics. 19(7):556–8. 
 Rosa Quinta, 2014  Page 75  
95. CENSUS 2011. Instituto Nacional de Estatística.  
http://censos.ine.pt/xportal/xmain?xpid=CENSOS&xpgid=censos 2011_apresentacao. 
96. Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N.. (2005) Temporal 
changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during 
pregnancy. Am. J. Obstet. Gynecol. 192(2):633–9. 
97. Bromek E., Haduch A., Daniel W.A.. (2009) The ability of cytochrome P450 2D 
isoforms to synthesize dopamine in the brain: An in vitro study. Eur. J. Pharmacol. 
626(2-3):171–8. 
98. Szarvas S., Harmon D., Murphy D.. (2003) Neuroaxial opioid-induced pruritus: a 
review. J. Clin. Anesth. 15:234–239. 
99. Horta M., Ramos L., Gonçalves Z.R.. (2000) The inhibition of epidural morphine-
induced pruritus by epidural droperidol. Anesth. Analg. 90:638–41.  
100. Meyer, U.A. (2004). Pharmacogenetics - five decades of therapeutic lessons from 
genetic diversity. Nature Reviews. Genetics, 5(9), 669–76. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“It’s far more important to know what person the 
disease has than what disease the person has.” 
Hippocrates 
